{"gene":"PTPN11","run_date":"2026-06-10T06:43:36","timeline":{"discoveries":[{"year":2001,"finding":"Missense mutations in PTPN11 (encoding SHP-2) cause Noonan syndrome. All mutations cluster in interacting portions of the N-SH2 domain and the phosphotyrosine phosphatase (PTP) domain involved in switching the protein between inactive and active conformations. Energetics-based structural analysis of two N-SH2 mutants indicates a significant shift of equilibrium favoring the active conformation, implying gain-of-function changes with excessive SHP-2 activity.","method":"Mutational analysis, energetics-based structural analysis of N-SH2 domain mutants","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — structural and energetics analysis combined with large-scale mutation screening; foundational paper replicated extensively","pmids":["11704759"],"is_preprint":false},{"year":2001,"finding":"H. pylori CagA protein is injected into host cells, undergoes tyrosine phosphorylation, and forms a physical complex with SHP-2 in a phosphorylation-dependent manner, stimulating SHP-2 phosphatase activity. Disruption of the CagA-SHP-2 complex abolished CagA-dependent cellular (growth factor-like) response, and the CagA effect was reproduced by constitutively active SHP-2.","method":"Co-immunoprecipitation, phosphatase activity assay, dominant-active SHP-2 expression, disruption of complex","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, phosphatase assay, functional rescue with constitutively active SHP-2; widely replicated","pmids":["11743164"],"is_preprint":false},{"year":1999,"finding":"SHP-2 and ERK signaling downstream of gp130 suppresses mouse ES cell self-renewal. A gp130 receptor mutant (Y118F) that fails to engage SHP-2 and cannot activate ERKs supports ES cell self-renewal at 100-fold lower cytokine concentrations with sustained STAT3 activation. MEK inhibitor PD098059 also enhanced undifferentiated ES cell growth, indicating that ERK activation actively impairs self-renewal.","method":"Chimeric receptor mutagenesis (Y118F), MEK inhibitor (PD098059), ES cell self-renewal assay, STAT3 activation measurement","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via receptor mutagenesis plus pharmacological inhibitor, multiple orthogonal methods","pmids":["10364425"],"is_preprint":false},{"year":1998,"finding":"Shp-2 is required for cell spreading, migration, and regulation of focal adhesion architecture. Fibroblasts lacking functional Shp-2 show impaired spreading and migration on fibronectin, increased focal adhesions, and condensed F-actin. FAK dephosphorylation was significantly reduced in Shp-2 mutant cells in suspension, and regulated association of Src SH2 domain with FAK and paxillin during cell attachment/detachment on fibronectin was disrupted.","method":"Genetic knockout (Shp-2 mutant fibroblasts), fibronectin adhesion/migration assays, biochemical analysis of FAK phosphorylation, Src-FAK-paxillin co-IP","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with defined cellular phenotype plus biochemical pathway analysis; replicated by other labs","pmids":["9694867"],"is_preprint":false},{"year":1999,"finding":"Shp-2 functions as a negative regulator of the interferon-stimulated JAK/STAT pathway. Shp-2-deficient fibroblasts show augmented suppression of cell viability and markedly elevated STAT1 tyrosine phosphorylation and DNA binding upon IFN-α or IFN-γ stimulation. Reintroduction of wild-type Shp-2 reversed hypersensitivity to IFNs and excessive STAT activation.","method":"Shp-2 knockout fibroblasts, EMSA (hSIE probe), Western blot for STAT1 phosphorylation, rescue with wild-type Shp-2 re-expression","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic loss-of-function plus functional rescue, multiple orthogonal methods in single study","pmids":["10022928"],"is_preprint":false},{"year":2003,"finding":"Somatic PTPN11 mutations occur in juvenile myelomonocytic leukemia (JMML) and are largely mutually exclusive with RAS and NF1 mutations, suggesting mutant SHP-2 proteins deregulate myeloid growth through Ras. Ba/F3 cells expressing leukemia-associated SHP-2 proteins showed enhanced growth factor-independent survival.","method":"Mutation screening, Ba/F3 cell growth factor-independence assay, biochemical analysis of ERK/Akt","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutation screening plus functional cell assay; single study, ERK/Akt hyperactivation was negative","pmids":["14644997"],"is_preprint":false},{"year":2004,"finding":"Noonan syndrome-associated SHP-2/PTPN11 mutants have increased basal phosphatase activity and, after EGF stimulation, show prolonged binding to GAB1 and sustained ERK2/MAPK1 activation. Coexpression of GAB1-FF (lacking SHP-2 binding motifs) blocked EGF-mediated increase in SHP-2 phosphatase activity and dramatically reduced ERK2 activation.","method":"Phosphatase activity assays, co-immunoprecipitation of GAB1-SHP-2, ERK2 activation (Western blot), GAB1-FF dominant-negative expression","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (phosphatase assay, co-IP, dominant-negative rescue) in single study","pmids":["14974085"],"is_preprint":false},{"year":2011,"finding":"Hepatocyte-specific deletion of Shp2 promotes inflammatory signaling through the Stat3 pathway, leading to hepatic inflammation/necrosis, regenerative hyperplasia, and tumor development in aged mice. Concurrent deletion of Shp2 and Stat3 abolished DEN-induced hepatocellular carcinoma, establishing a Stat3-dependent tumor-suppressor function for Shp2 in liver.","method":"Hepatocyte-specific conditional knockout (Cre-lox), genetic epistasis (double Shp2/Stat3 KO), DEN-induced HCC model","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific KO with genetic epistasis rescue, rigorous in vivo model","pmids":["21575863"],"is_preprint":false},{"year":1993,"finding":"SH-PTP2 (SHP-2) associates in vivo with ligand-activated EGF and PDGF receptors via its N-terminal SH2 domain. SH-PTP2 itself becomes tyrosyl phosphorylated upon growth factor activation.","method":"Co-immunoprecipitation from cells, SH2 domain direct binding assay, phosphotyrosine Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct binding assay plus in vivo co-IP; widely replicated foundational finding","pmids":["8514779"],"is_preprint":false},{"year":1994,"finding":"PTP2C (SHP-2) rapidly dephosphorylates tyrosine-phosphorylated IRS-1. The SH2 domains of PTP2C enhance its activity toward IRS-1 (dephosphorylation by the SH2 domain-deleted form was ~3-fold slower), suggesting that SH2-domain binding to pY-IRS-1 allosterically activates the phosphatase toward this substrate.","method":"In vitro phosphatase assay with recombinant IRS-1 and truncated PTP2C, comparison of full-length vs. SH2-deleted enzyme","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstituted phosphatase assay with defined substrates and domain-deletion variants","pmids":["7515062"],"is_preprint":false},{"year":1997,"finding":"SHP-2 is tyrosine-phosphorylated by JAK1 and JAK2 (but not JAK3) and associates with them. The SH2 domains of SHP-2 are not essential for JAK binding; instead, amino acids 232–272 in SHP-2 mediate the interaction. JAKs phosphorylate SHP-2 on Y304 and Y327, and phosphorylated SHP-2 associates with the adaptor Grb2. The N-terminus of JAK2 (not its kinase-like domain) is required for association with SHP-2.","method":"COS-1 cell co-transfection, co-immunoprecipitation, domain-deletion/point-mutation mapping, kinase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic domain-deletion and phosphosite mutagenesis with co-IP; multiple orthogonal methods","pmids":["8995399"],"is_preprint":false},{"year":2000,"finding":"Shp-2 acts upstream of RhoA to regulate its activity. Perturbation of Shp-2 activity by genetic manipulations (including catalytically inactive mutants and deletion) results in raised levels of active RhoA. Calpeptin, which interferes with Shp-2 catalytic activity in vitro, also elevates active RhoA in vivo.","method":"Genetic manipulation of Shp-2 (dominant negative and null), RhoA activity assay (GTP-loading), in vitro calpeptin inhibition of Shp-2","journal":"Current biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic strategies plus in vitro biochemical assay, epistatic placement of Shp-2 upstream of RhoA","pmids":["11114521"],"is_preprint":false},{"year":2001,"finding":"SHP-2 is required for mediating PI3K/Akt activation by growth factors (EGF, PDGF, IGF). Deletion of the N-terminal SH2 domain of SHP-2 severely impaired PDGF- and IGF-induced Akt phosphorylation. EGF stimulation induced co-immunoprecipitation of the p85 subunit of PI3K with SHP-2. Ectopic wild-type SHP-2 expression elevated EGF-induced Akt phosphorylation in an N-terminal SH2-domain-dependent manner.","method":"SHP-2 domain-deletion (exon 3) cell lines, co-immunoprecipitation of PI3K p85 with SHP-2, Akt phosphorylation (Western blot), lipid kinase assay, reconstitution in SHP-2-/- fibroblasts","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cell models, co-IP, lipid kinase assay, domain-deletion mutagenesis","pmids":["11593409"],"is_preprint":false},{"year":2003,"finding":"Shp-2 is a Stat5A phosphatase. Shp-2 (but not Shp-1) specifically interacted with tyrosine-phosphorylated Stat5A in vivo. Shp-2 accelerated Stat5A dephosphorylation, and dephosphorylation of Stat5A was dramatically delayed in Shp-2-deficient cells.","method":"Affinity purification using pY-Stat5A peptides, co-immunoprecipitation, dephosphorylation kinetics assay, Shp-2-deficient cell comparison","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — biochemical substrate identification plus genetic loss-of-function confirmation","pmids":["12615921"],"is_preprint":false},{"year":1998,"finding":"Both SH2 domains and the PTP catalytic domain of SHP-2 are required for normal function in Xenopus mesoderm induction. The N-terminal SH2 domain is absolutely required, the C-terminal SH2 contributes to wild-type function, whereas C-terminal tyrosyl phosphorylation sites and proline-rich region are dispensable. SHP-2/SHP-1 chimera studies revealed that substantial specificity resides in the PTP domain itself.","method":"Xenopus mesoderm induction assay, domain-deletion and chimera mutagenesis (SHP-2/SHP-1 chimeras), functional readout (mesoderm induction, gastrulation)","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — systematic domain mutagenesis with in vivo functional readout, multiple mutants tested","pmids":["9418864"],"is_preprint":false},{"year":2004,"finding":"SHP-2 positively regulates myogenesis by dephosphorylating p190-B RhoGAP, which promotes RhoA activation. SHP-2 substrate-trapping mutants identified p190-B RhoGAP as a direct SHP-2 substrate. During myogenesis, p190-B RhoGAP tyrosyl dephosphorylation correlated with SHP-2 phosphatase activation; a catalytically inactive SHP-2 mutant inhibited p190-B RhoGAP dephosphorylation, RhoA activity, and myogenesis.","method":"SHP-2 substrate-trapping mutants, co-immunoprecipitation, RhoA activity assay, catalytically inactive SHP-2 overexpression, RNAi knockdown","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — substrate trapping identifies direct substrate, multiple orthogonal approaches, epistatic placement","pmids":["15169898"],"is_preprint":false},{"year":1999,"finding":"SHP-2 dephosphorylates the PDGF receptor, yet enhances PDGF-induced MAP kinase pathway activation. Catalytically active SHP-2 decreased PDGF receptor tyrosine phosphorylation while enhancing MAP kinase activation; catalytically inactive SHP-2 had the opposite effects.","method":"Co-expression of active/inactive SHP-2 with PDGF receptor in HEK293 cells, receptor phosphorylation assay, MAP kinase activation assay","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-expression with active/inactive mutants, single lab, two orthogonal readouts","pmids":["9931295"],"is_preprint":false},{"year":2006,"finding":"Gain-of-function SHP-2 mutants (Noonan syndrome-associated) enhance FGF-2-mediated Ca2+ oscillations in fibroblasts and spontaneous Ca2+ oscillations in cardiomyocytes. Enhanced Ca2+ oscillation frequency correlates with reduced nuclear translocation and transcriptional activity of NFAT, dependent on SHP-2 phosphatase activity.","method":"Ca2+ oscillation imaging, NFAT nuclear translocation assay, gain-of-function SHP-2 mutant expression in fibroblasts and cardiomyocytes","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell Ca2+ imaging plus transcription factor localization assay, single lab","pmids":["16461457"],"is_preprint":false},{"year":2009,"finding":"Shp-2 is an essential component of Neuregulin-1/ErbB signaling in Schwann cells. Conditional mutation of Shp2 in neural crest cells/Schwann cells abolished Nrg1-evoked proliferation and migration and altered Nrg1-dependent intracellular signaling. Pharmacological inhibition of Src family kinases mimicked all effects, implicating Src as a primary Shp-2 target during Nrg1 signaling.","method":"Conditional knockout (neural crest/Schwann cell-specific), Schwann cell proliferation/migration assays, Src family kinase inhibitor phenocopy","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific genetic KO plus pharmacological epistasis, multiple orthogonal methods","pmids":["19805360"],"is_preprint":false},{"year":1997,"finding":"SHP-2 (but not SHP-1) associates with tyrosine-phosphorylated PECAM-1 (CD31) via its SH2 domains following integrin or immune receptor activation. SHP-2 SH2 domain fusion protein directly bound phosphorylated PECAM-1, and SHP-2 dephosphorylated PECAM-1 in immune precipitate phosphatase assays.","method":"Co-immunoprecipitation, SH2 domain GST-pulldown, direct binding to pY-PECAM-1, immune-complex phosphatase assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus direct binding plus in vitro phosphatase assay, single lab","pmids":["9388260"],"is_preprint":false},{"year":2005,"finding":"TCR activation induces ROS-dependent transient inactivation (oxidation) of SHP-2's active site cysteine. SHP-2 is recruited to the LAT-Gads-SLP-76 complex and directly regulates phosphorylation of Vav1 and ADAP. ADAP association with SLP-76 is regulated by SHP-2 in a redox-dependent manner, promoting T-cell adhesion through integrin activation.","method":"Oxidation assay of active-site cysteine, co-immunoprecipitation with LAT/Gads/SLP-76 complex, phosphorylation analysis of Vav1/ADAP, T-cell adhesion assay","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct redox assay plus co-IP plus functional adhesion readout, single lab","pmids":["15933714"],"is_preprint":false},{"year":2006,"finding":"SHP-2 negatively regulates TRIF-dependent TLR signaling by directly binding TANK-binding kinase 1 (TBK1) via its C-terminal domain (interaction with TBK1 kinase domain), independent of phosphatase activity. SHP-2 deficiency increased TBK1-activated IFN-β and TNF-α expression. SHP-2 also inhibited poly(I:C)-induced MAP kinase pathway activation.","method":"Co-immunoprecipitation of SHP-2 C-terminal domain with TBK1, SHP-2-deficient cell analysis, TBK1 knockdown epistasis, cytokine measurement","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — domain mapping of interaction, genetic KO, epistasis (TBK1 KD), phosphatase-independent mechanism established by multiple methods","pmids":["17157040"],"is_preprint":false},{"year":2011,"finding":"SHP-2 (PTPN11) is required for PDGFRA-driven gliomagenesis in Ink4a/Arf-deficient cells. Abrogation of SHP-2-binding motifs in PDGFRα or SHP-2 shRNA knockdown disrupted PI3K interaction with PDGFRα, suppressed AKT/mTOR activation, and impaired tumorigenesis. Activated PI3K mutant expression rescued the effect of SHP-2 inhibition, placing SHP-2 upstream of PI3K in this pathway.","method":"Receptor mutagenesis (SHP-2 binding site ablation), shRNA knockdown, pharmacological SHP-2 inhibition, activated PI3K rescue, in vivo glioma model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — receptor mutagenesis plus genetic KD plus genetic rescue, multiple orthogonal methods in vivo and in vitro","pmids":["21393858"],"is_preprint":false},{"year":2013,"finding":"S-nitrosylation of SHP-2 at its active-site cysteine by NO (forming SNO-SHP-2) inhibits its phosphatase activity in neurons. NMDA exposure and transient focal cerebral ischemia increased SNO-SHP-2 levels, blocking downstream ERK1/2 neuroprotective signaling and increasing susceptibility to NMDA receptor-mediated excitotoxicity.","method":"S-nitrosylation assay (biotin-switch), phosphatase activity assay of SNO-SHP-2, NMDA treatment in vitro, focal ischemia model in vivo, ERK1/2 activation assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct PTM identification with biochemical activity assay, in vitro and in vivo models","pmids":["23382182"],"is_preprint":false},{"year":2005,"finding":"Tyrosine phosphatase SHP-2 negatively regulates TrkB receptor activity in cerebellar neurons under conditions of excessive calcium influx. Calcium influx (via L-type channels or glutamate receptors) enhanced association of Shp-2 with TrkB receptors, inhibiting BDNF-induced TrkB autophosphorylation and downstream Ras/Erk/Akt activation. Deletion of the Shp2 gene reversed inhibition of TrkB and increased neuronal survival.","method":"Shp-2 gene deletion in neuronal cultures, co-immunoprecipitation of Shp-2 with TrkB, TrkB autophosphorylation assay, neuronal survival assay with depolarization/glutamate","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO plus co-IP plus functional rescue, multiple orthogonal methods","pmids":["15650750"],"is_preprint":false},{"year":2008,"finding":"SHP-2 is a novel substrate of Abl family kinases during growth factor-mediated proliferation. Endogenous Abl kinases phosphorylate SHP-2 on Y580, inducing sustained ERK activation. Abl kinases also indirectly mediate phosphorylation of SHP-2 on Y63 and Y279; phosphorylation of Y279 downregulates sustained ERK activation and proliferation, constituting a negative-feedback mechanism.","method":"Pharmacological Abl inhibition (imatinib), RNAi knockdown, site-directed mutagenesis of SHP-2 phosphorylation sites, ERK activation assay, proliferation (G1-to-S) assay","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibitor and RNAi plus phosphosite mutagenesis, single lab","pmids":["18827006"],"is_preprint":false},{"year":2006,"finding":"SHP-2 is required for hematopoietic cell transformation by Bcr-Abl. SHP-2 interacts with Hsp90, and loss of SHP-2 leads to proteasome-mediated degradation of p210 Bcr-Abl independently of SHP-2's catalytic activity. Inhibition of SHP-2 enzymatic activity (without destabilizing p210) also enhanced apoptosis, indicating a dual role (chaperone and signaling) of SHP-2 in Bcr-Abl leukemogenesis.","method":"Shp-2 conditional deletion in hematopoietic cells, leukemia transplantation model, Hsp90 co-immunoprecipitation, proteasome inhibitor rescue, antisense/siRNA knockdown, catalytically inactive SHP-2 overexpression","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with in vivo model, co-IP with Hsp90, pharmacological rescue, multiple orthogonal methods","pmids":["17003374"],"is_preprint":false},{"year":2016,"finding":"Gain-of-function Ptpn11 mutations disturb mitosis and cytokinesis, causing chromosomal instability. Shp-2 localizes to the kinetochore, centrosome, spindle midzone, and midbody. GOF mutant Shp-2 hyperactivates Polo-like kinase 1 (Plk1) by enhancing c-Src kinase-mediated tyrosine phosphorylation of Plk1.","method":"Immunofluorescence localization of Shp-2 to mitotic structures, Plk1 kinase assay, c-Src kinase assay, MEFs from Ptpn11 GOF knock-in mice, chromosomal instability analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct localization plus kinase activity assay plus genetic model, multiple orthogonal methods","pmids":["26755576"],"is_preprint":false},{"year":2020,"finding":"SHP-2 bridges two PD-1 molecules by simultaneously engaging phosphorylated ITSM-Y248 residues on two PD-1 cytoplasmic tails via its N-SH2 and C-SH2 domains, forming a PD-1:PD-1 dimer. This dual engagement induces robust SHP-2 enzymatic activation. The interaction and activation depend exclusively on ITSM-Y248.","method":"Isothermal titration calorimetry (ITC), PD-1 dimerization in live cells, SHP-2 enzymatic activation assay with ITSM phosphopeptides, site-directed mutagenesis","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ITC biophysical measurement plus live-cell interaction assay plus enzymatic activation assay, multiple orthogonal methods","pmids":["32184441"],"is_preprint":false},{"year":2007,"finding":"In zebrafish, Shp-2 is required for convergence and extension cell movements during gastrulation. Shp-2 knockdown-induced defects were rescued by active Fyn, active Yes (Src family kinases), and active RhoA, placing Src family kinases and RhoA downstream of Shp-2 in this process. Noonan syndrome Shp-2 mutants are activated (gain-of-function) while LEOPARD syndrome mutants lack catalytic activity; both cause convergence/extension defects.","method":"Morpholino knockdown in zebrafish, cell tracing experiments, epistatic rescue with constitutively active Fyn/Yes/RhoA, in situ hybridization, expression of patient-derived mutants","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — morpholino KD plus multiple epistatic rescues, cell tracing, multiple orthogonal approaches","pmids":["18159945"],"is_preprint":false},{"year":2011,"finding":"The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy (HCM) by dysregulating mTOR signaling. Cardiomyocyte-specific overexpression of Q510E-Shp2 hyperactivated Akt/mTOR signaling, and rapamycin treatment rescued the HCM phenotype both prophylactically and therapeutically. Normal Shp-2 controls cardiomyocyte size by regulating Akt/mTOR.","method":"Cardiomyocyte-specific transgenic mouse model, Akt/mTOR phosphorylation (Western blot), rapamycin rescue, echocardiography, histology","journal":"American journal of physiology. Heart and circulatory physiology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain-of-function mouse model plus pharmacological rescue, functional cardiac phenotyping","pmids":["22058153"],"is_preprint":false},{"year":2012,"finding":"In Xenopus, SHP-2 regulates the cardiac actin cytoskeleton via ROCK. Noonan syndrome SHP-2 mutations cause cardiac cell cycle arrest in M-phase, failure of cardiomyocyte progenitors to incorporate into the developing heart, and defective actin fiber formation and polarity. ROCK inhibition rescued these cardiac defects, demonstrating that SHP-2(N308D) signals through ROCK to regulate the cardiac actin cytoskeleton.","method":"Xenopus cardiac development model, Noonan/JMML mutant SHP-2 expression, ROCK inhibitor rescue, F-actin staining, cardiac cell cycle analysis","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain-of-function plus pharmacological epistasis (ROCK inhibitor rescue), multiple cellular readouts","pmids":["22278918"],"is_preprint":false},{"year":2007,"finding":"In Xenopus, SHP-2 activity is required for maintenance and survival of proliferating cardiac progenitor cells. SHP-2 is phosphorylated on Y542/Y580 and binds to FRS-2, placing SHP-2 in the FGF pathway during early embryonic heart development. FGF signaling inhibition mimics SHP-2 inhibition effects, and constitutively active/Noonan-associated SHP-2 rescues FGF signaling inhibition.","method":"Xenopus cardiac progenitor assay, SHP-2 phosphorylation analysis (Y542/Y580), FRS-2 co-immunoprecipitation, FGF inhibitor phenocopy, constitutively active SHP-2 rescue","journal":"Development","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP binding, phosphorylation mapping, FGF inhibitor epistasis, rescue experiment","pmids":["17928416"],"is_preprint":false},{"year":2001,"finding":"Shp-2 is required for lymphoid and hematopoietic cell development across all blood cell lineages. Shp-2-/- ES cells in RAG-2-deficient blastocyst complementation yielded no mature T or B cells, nor precursor lymphocytes. Shp-1 deficiency (me(v)/me(v)) partially rescued Shp-2-/- hematopoietic defects, demonstrating antagonistic roles for Shp-1 and Shp-2 in hematopoiesis via the same signaling pathway(s).","method":"RAG-2-deficient blastocyst complementation, double Shp-2-/-/mev/mev mutant analysis, yolk sac hematopoiesis quantification","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in vivo with blastocyst complementation and double mutant analysis","pmids":["11159516"],"is_preprint":false},{"year":2018,"finding":"Large-scale phosphoproteomics identified Shp-2 as the master regulator of PDGF receptor (Pdgfr) pTyr signaling. Allosteric Shp-2 inhibition revealed global regulation of the Pdgf-dependent tyrosine phosphoproteome. Key Shp-2-dependent targets include Rasa1 and Cortactin (increased pTyr upon Shp-2 inhibition) and Gab1 and Erk1/2 (decreased pTyr). Shp-2 inhibition significantly impaired PDGF-stimulated cell migration.","method":"Quantitative phosphoproteomics (>40,000 phosphorylation sites), allosteric Shp-2 inhibitor (SHP099), cell migration assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — large-scale unbiased substrate identification plus functional cell migration assay, comprehensive coverage","pmids":["29514104"],"is_preprint":false},{"year":2011,"finding":"Substrate specificity profiling by combinatorial peptide library screening established that SHP-2 shares similar but narrower substrate specificities with SHP-1: both strongly prefer acidic and aromatic hydrophobic amino acids flanking the pY residue, with preference for ≥2 acidic residues N-terminal and ≥1 acidic residue C-terminal to pY, and exclusion of basic residues. The in vitro specificity profile agreed with in vivo dephosphorylation patterns of known SHP-2 substrates.","method":"On-bead screening of combinatorial phosphotyrosyl peptide libraries, solution-phase kinetic analysis of individually synthesized pY peptides","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstituted assay with combinatorial library screening and kinetic validation","pmids":["21291263"],"is_preprint":false},{"year":2012,"finding":"SHP-2 regulates osteoclastogenesis by promoting preosteoclast fusion, required for formation of giant multinucleated osteoclasts. OC-specific Shp2 knockout mice are osteopetrotic. Shp-2 is required for RANKL-induced upregulation of Nfatc1 (master transcription factor for terminal OC differentiation). Shp-2 deletion had minimal effect on M-CSF-dependent OC precursor survival/proliferation.","method":"Osteoclast-specific conditional Shp2 knockout, microCT bone analysis, RANKL-induced Nfatc1 expression assay, cell fusion assay, pharmacological Shp2 inhibition","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific KO with comprehensive bone phenotyping plus molecular pathway analysis","pmids":["25593124"],"is_preprint":false},{"year":2012,"finding":"SHP-2 is required for leucine-induced S6K1 activation in skeletal myoblasts via mobilization of intracellular Ca2+ in an IP3-dependent manner. SHP-2 acts upstream of phospholipase C β4 to generate nutrient-induced Ca2+ release and S6K1 phosphorylation. SHP-2-deficient myoblasts have impaired leucine sensing, defective autophagy, and reduced myoblast size.","method":"SHP-2 knockout/overexpression in myoblasts, S6K1 phosphorylation assay, Ca2+ mobilization assay, IP3 measurement, PLC β4 epistasis, autophagy assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO plus multiple biochemical readouts, single lab","pmids":["23129808"],"is_preprint":false},{"year":2019,"finding":"Shp-2 is critical for ERK activation and metabolic engagement (glycolysis and respiration) downstream of IL-15 receptor in NK cells. Shp-2-deficient NK cells show dramatic defect in ERK activation and reduced metabolic burst upon IL-15/IL-2 stimulation, leading to impaired proliferation and survival. ERK and mTOR cascade inhibition phenocopied Shp-2 deficiency.","method":"NK cell-specific conditional Shp-2 KO, ERK phosphorylation assay, Seahorse metabolic flux analysis, pharmacological ERK/mTOR inhibitor epistasis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic KO plus pharmacological epistasis plus metabolic assay, multiple orthogonal methods","pmids":["30926899"],"is_preprint":false},{"year":2018,"finding":"Genetic deletion of Ptpn11 profoundly inhibits tumor development in mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) and non-small-cell lung cancer mouse models. SHP-2 is necessary for resistance mechanisms upon MEK blockade. Dual SHP2/MEK inhibition achieves synergistic tumor growth control in KRAS-mutant PDAC and NSCLC.","method":"Genetic Ptpn11 deletion in KRAS-driven mouse tumor models, MEK inhibitor combination, patient-derived organoids and xenograft models","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo genetic KO plus pharmacological combination, multiple tumor models including human patient-derived material","pmids":["29808009"],"is_preprint":false},{"year":2018,"finding":"X-ray crystallography identified a second allosteric binding site on SHP2 at the interface of the N-terminal SH2 and PTP domains (distinct from the tunnel-like SHP099 site). SHP244 binds and stabilizes the inactive closed conformation of SHP2 at this site. Simultaneous occupation of both allosteric sites is possible, demonstrating cooperative dual allosteric inhibition and enhanced MAPK pathway suppression.","method":"X-ray crystallography of SHP2/inhibitor complexes, cooperative biochemical inhibition assays, DUSP6 mRNA assay in cancer cells, structure-based design","journal":"ACS chemical biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures of multiple complexes plus biochemical cooperativity assay","pmids":["29304282"],"is_preprint":false},{"year":2013,"finding":"SHP-2 directly interacts with ICAM-1 and VE-cadherin in endothelial cells. SHP-2 downregulation enhanced neutrophil adhesion but inhibited transmigration. ICAM-1 activation leads to SHP-2-mediated Src activation and VE-cadherin switching from ICAM-1 association to actin association; SHP-2 downregulation prevented ICAM-1-VE-cadherin association and promoted VE-cadherin-actin association.","method":"siRNA knockdown of SHP-2, co-immunoprecipitation of ICAM-1/SHP-2/VE-cadherin, neutrophil adhesion/transmigration assay, in vivo LPS lung model","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus siRNA KD plus in vivo model, single lab","pmids":["28701303"],"is_preprint":false},{"year":2019,"finding":"In sepsis, ROS-dependent inactivation of SHP-2 in endothelial cells drives vascular dysfunction. SHP-2 directly interacts with the IL-1R1 adaptor MyD88 via its tyrosine 257, resulting in reduced binding of p85/PI3K to MyD88. SHP-2 activity inversely correlates with adhesion molecule expression through p38 MAPK and NF-κB.","method":"Proximity ligation assay for SHP-2/MyD88 interaction, SHP-2 phosphatase activity assay, ROS inhibitor rescue, in vivo sepsis model, in vitro endothelial cell model, Y257 mutagenesis","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — proximity ligation assay plus phosphatase assay plus site-directed mutagenesis, single lab","pmids":["30905847"],"is_preprint":false},{"year":2013,"finding":"Intestinal epithelial cell-specific deletion of SHP-2 leads to severe colitis with hyperactivation of Stat3 and NF-κB, decreased claudin expression and enhanced intestinal permeability. Antibiotic treatment markedly impaired colitis development, indicating a microbiota-dependent mechanism.","method":"Intestinal epithelial cell-specific conditional KO (SHP-2(IEC-KO) mice), histology, cytokine analysis, intestinal permeability assay, Western blot for Stat3/NF-κB, antibiotic treatment","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — tissue-specific genetic KO with comprehensive mechanistic analysis, multiple orthogonal methods","pmids":["23530062"],"is_preprint":false},{"year":2022,"finding":"In myeloid cells, SHP-2 restrains GM-CSF-induced phosphorylation of transcription factors HOXA10 and IRF8, which regulate myeloid differentiation and monocytic-moDC lineage commitment. GM-CSF induces phosphorylation of PD-1 and recruitment of PD-1-SHP-2 to the GM-CSF receptor. Myeloid-specific deletion of SHP-2 or PD-1 diminishes tumor growth via enhanced myeloid differentiation.","method":"Myeloid-specific conditional SHP-2 or PD-1 KO mice, RNA-seq/GSEA, HOXA10/IRF8 phosphorylation assay, co-immunoprecipitation of PD-1-SHP-2 with GM-CSF receptor, tumor growth assay","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific genetic KO, co-IP of receptor complex, downstream TF phosphorylation analysis, multiple orthogonal methods","pmids":["36581713"],"is_preprint":false},{"year":1999,"finding":"BIT (brain immunoglobulin-like molecule with tyrosine-based activation motifs) associates with SHP-2 via its tyrosine-phosphorylated TAMs upon neurotrophin (NGF, BDNF, NT-3) stimulation, and this association potently stimulates SHP-2 phosphatase activity in neurons.","method":"Co-immunoprecipitation after neurotrophin treatment, in vitro SHP-2 phosphatase activation assay with pY-BIT","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus phosphatase activation assay, single lab","pmids":["10098842"],"is_preprint":false},{"year":2013,"finding":"RSK (p90 ribosomal S6 kinase) phosphorylates Gab2 on conserved residues upon Ras/MAPK pathway activation, and this phosphorylation inhibits recruitment of SHP-2 to Gab2 in response to growth factors. An unphosphorylatable Gab2 mutant promotes invasion-like phenotype and increased cell motility, indicating that RSK-mediated Gab2 phosphorylation constitutes a negative-feedback loop restricting Gab2-dependent SHP-2 recruitment and epithelial cell motility.","method":"In vitro RSK kinase assay with Gab2, phosphosite mutagenesis, co-immunoprecipitation of Gab2-SHP-2 after growth factor stimulation, invasion/motility assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay plus co-IP plus mutagenesis plus functional cell assay, single lab","pmids":["23401857"],"is_preprint":false},{"year":2014,"finding":"Crystal structures of wild-type SHP2 and five NS/LS-associated PTPN11 mutants reveal local conformational changes caused by each mutation. NS mutations shift conformational equilibrium toward the active open state; LS mutations have distinct structural consequences consistent with loss of catalytic activity. Structural analysis provides mechanistic insight into the distinct catalytic properties of disease-associated mutants.","method":"X-ray crystallography of WT and mutant SHP2 proteins","journal":"BMC structural biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structures of multiple disease mutants with direct conformational comparison, single study","pmids":["24628801"],"is_preprint":false},{"year":2002,"finding":"Gab1-SHP-2 interaction is required for EGF-induced Ras activation and epidermal proliferation. Gab1(Y627F) deficient in SHP-2 binding or dominant-negative SHP-2(C459S) reduced active Ras and downstream MAPK levels and initiated keratinocyte differentiation. Active Ras rescued the differentiation induced by Gab1(Y627F) and SHP-2(C459S), placing Gab1 and SHP-2 upstream of Ras in epidermal homeostasis.","method":"Gab1(Y627F) and SHP-2(C459S) overexpression in epidermal cells, Ras activity assay, Ras rescue epistasis, tissue reconstruction model, Gab1-/- murine epidermis analysis","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic tools (dominant negative, site mutant, KO epidermis) plus Ras activity assay plus genetic rescue","pmids":["12370245"],"is_preprint":false},{"year":2000,"finding":"SHP-2 is required for Ras-dependent JNK activation by insulin and EGF. A catalytically inactive SHP-2(C/S) mutant markedly inhibited Ras activation in response to insulin without affecting insulin-induced tyrosine phosphorylation of substrates. SHP-2(C/S) did not inhibit JNK activation induced by constitutively active Ras(V12), placing SHP-2 at the level of or upstream of SOS in insulin-mediated JNK activation.","method":"Catalytically inactive SHP-2(C/S) overexpression, JNK/ERK activation assay, Ras-GTP loading assay, dominant-negative Ras/Rac epistasis, PI3K inhibitor","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple epistatic experiments with defined pathway placement, single lab","pmids":["10671568"],"is_preprint":false},{"year":2004,"finding":"SHP-2 catalytic activity suppresses caspase 3-mediated apoptosis by regulating IGF-1-dependent PI3K and Akt activation. Catalytically inactive SHP-2 inhibited IGF-1-induced PI3K and Akt activation; SHP-2(Ex3-/-) fibroblasts showed enhanced caspase 3 activation upon etoposide treatment, rescued by re-introduction of wild-type SHP-2 or a caspase 3 inhibitor.","method":"Catalytically inactive SHP-2 overexpression, SHP-2(Ex3-/-) fibroblasts, PI3K/Akt assay, caspase 3 activity assay, WT-SHP-2 rescue, RNAi knockdown","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic deletion plus catalytic mutant plus rescue plus downstream kinase assay, single lab","pmids":["15040005"],"is_preprint":false},{"year":2008,"finding":"SHP-2 and Src are exclusively localized in brain (not muscle, heart, liver, or kidney) mitochondria. In brain mitochondria, ATP induces Src autophosphorylation at Tyr-416 (activation), and SHP-2 is present at this location; Src inhibition partially reversed ATP-induced increases in oxidative phosphorylation complexes I, III, and IV activity.","method":"Subcellular fractionation and immunodetection of PTP-1B, SHP-2, and Src in isolated mitochondria from multiple rat tissues, oxidative phosphorylation complex activity assays","journal":"The Journal of biological chemistry","confidence":"Low","confidence_rationale":"Tier 3 / Weak — fractionation/localization with functional inference, but SHP-2's own activity at this location was not directly tested; single lab","pmids":["18583343"],"is_preprint":false},{"year":2002,"finding":"In C2C12 myoblasts, FGF-2 stimulation induces SHP-2 complex formation with tyrosyl-phosphorylated FRS-2α. Both catalytic activity and (to a lesser extent) the Grb2-binding/tyrosyl-phosphorylation sites of SHP-2 are required for maximal FGF-2-induced Erk activation. A constitutively active SHP-2 mutant represses myogenesis via an Erk-independent pathway and induces hyper-tyrosyl phosphorylation of FRS-2α.","method":"Co-immunoprecipitation of SHP-2 with FRS-2α, Erk/Elk-1 activation assay, constitutively active and catalytically inactive SHP-2 overexpression, myogenesis assay","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus catalytic/constitutive mutants plus functional myogenesis assay, single lab","pmids":["11997521"],"is_preprint":false}],"current_model":"SHP-2 (PTPN11) is a cytoplasmic protein tyrosine phosphatase with two SH2 domains that is held in an autoinhibited closed conformation by intramolecular N-SH2/PTP domain interaction; binding of phosphotyrosine-containing ligands (growth factor receptors, docking proteins such as GAB1/FRS-2, and inhibitory receptor ITSMs such as PD-1) via its SH2 domains relieves autoinhibition and activates catalysis. It acts as a positive regulator of RAS/MAPK and PI3K/AKT signaling downstream of multiple receptor tyrosine kinases, cytokine receptors, and integrins—in part by dephosphorylating negative regulators (e.g., p190-B RhoGAP, PDGFR, STAT5A) and stabilizing signaling complexes—while also serving as a negative regulator of JAK/STAT, RhoA (via RhoGAP dephosphorylation), and TRIF-dependent TLR/TBK1 pathways; disease-causing gain-of-function mutations (Noonan syndrome, leukemia) shift the conformational equilibrium toward the active state, whereas loss-of-function mutations (LEOPARD syndrome) abolish catalytic activity, and both classes disrupt convergence/extension cell movements, cardiac development, and hematopoiesis through dysregulation of ERK, mTOR, RhoA/ROCK, and Ca²⁺/NFAT signaling."},"narrative":{"mechanistic_narrative":"SHP-2 (PTPN11) is a cytoplasmic protein tyrosine phosphatase that serves as a central positive amplifier of receptor tyrosine kinase and cytokine signaling toward the RAS/MAPK and PI3K/AKT pathways, while acting as a negative regulator of several inhibitory and inflammatory circuits [PMID:8514779, PMID:11593409, PMID:29514104]. Its activity is governed by a conformational switch: disease-associated Noonan-syndrome mutations cluster at the interacting N-SH2/PTP interface and shift the equilibrium toward the active open state, whereas LEOPARD-syndrome mutations abolish catalytic activity, mechanisms confirmed by crystallography of wild-type and mutant proteins [PMID:11704759, PMID:24628801]. Physiologically, the SH2 domains engage phosphotyrosine ligands—growth-factor receptors, docking proteins such as GAB1 and FRS-2, and inhibitory receptor ITSMs such as PD-1—to relieve autoinhibition and stimulate catalysis; PD-1 engagement bridges two receptor tails through both SH2 domains to robustly activate the enzyme [PMID:14974085, PMID:32184441, PMID:17928416, PMID:12370245]. SHP-2 promotes RAS activation upstream of SOS and drives sustained ERK signaling downstream of EGF, PDGF, FGF, and insulin, paradoxically enhancing MAPK output even while dephosphorylating receptors such as PDGFR [PMID:9931295, PMID:12370245, PMID:10671568, PMID:29514104], and it supports PI3K/AKT/mTOR signaling required for survival, cell size control, and tumorigenesis [PMID:11593409, PMID:21393858, PMID:22058153]. Direct substrates include p190-B RhoGAP (linking SHP-2 to RhoA activation and myogenesis), STAT5A, IRS-1, and PDGFR, and unbiased phosphoproteomics establishes SHP-2 as a master regulator of the PDGFR phosphotyrosine network controlling targets including RASA1, cortactin, and GAB1 [PMID:7515062, PMID:12615921, PMID:15169898, PMID:29514104]. As a negative regulator it dampens JAK/STAT signaling, restrains TRIF-dependent TLR/TBK1 responses via a phosphatase-independent C-terminal interaction with TBK1, and limits Schwann cell, T-cell, NK-cell, osteoclast, and myeloid responses [PMID:10022928, PMID:17157040, PMID:19805360, PMID:15933714, PMID:30926899, PMID:25593124, PMID:36581713]. SHP-2 is essential for hematopoietic and lymphoid development, cell spreading and migration through FAK/Src, and convergence-extension movements during gastrulation via Src-family kinases and RhoA [PMID:9694867, PMID:11159516, PMID:18159945]. Its activity is itself tuned by oxidative and nitrosative modification of the active-site cysteine and by Abl-mediated phosphorylation feedback [PMID:23382182, PMID:15933714, PMID:18827006]. PTPN11 mutations cause Noonan syndrome and LEOPARD-syndrome/hypertrophic cardiomyopathy and underlie somatic transformation in juvenile myelomonocytic leukemia and KRAS-driven solid tumors [PMID:11704759, PMID:22058153, PMID:14644997, PMID:29808009].","teleology":[{"year":1993,"claim":"Established that SHP-2 is physically coupled to activated growth factor receptors, providing the first link between the phosphatase and RTK signaling.","evidence":"Co-IP and SH2 direct-binding assays showing SH-PTP2 binds activated EGFR/PDGFR via its N-SH2 domain and is itself tyrosine-phosphorylated","pmids":["8514779"],"confidence":"High","gaps":["Did not determine functional consequence of receptor binding","Substrates downstream of receptor recruitment not identified"]},{"year":1994,"claim":"Showed SHP-2 actively dephosphorylates a defined substrate (IRS-1) and that its SH2 domains allosterically enhance catalysis, foreshadowing the autoinhibition model.","evidence":"In vitro phosphatase assay comparing full-length versus SH2-deleted enzyme on pY-IRS-1","pmids":["7515062"],"confidence":"High","gaps":["Structural basis of SH2-mediated activation not resolved","Physiological relevance of IRS-1 dephosphorylation not tested in vivo"]},{"year":1999,"claim":"Resolved that SHP-2 has opposing roles on different pathways—positively engaging ERK while negatively regulating JAK/STAT.","evidence":"gp130 Y118F receptor mutant in ES cells, MEK inhibitor, and Shp-2-deficient fibroblasts with elevated STAT1 phosphorylation rescued by WT re-expression","pmids":["10364425","10022928"],"confidence":"High","gaps":["Direct STAT substrate dephosphorylation not biochemically demonstrated here","Mechanism of ERK activation versus receptor dephosphorylation paradox unresolved"]},{"year":1998,"claim":"Defined the domain requirements for SHP-2 function and placed it in cell adhesion/cytoskeletal control via FAK and Src.","evidence":"Xenopus mesoderm induction with domain-deletion/chimera mutants; Shp-2 mutant fibroblasts with impaired spreading and reduced FAK dephosphorylation","pmids":["9418864","9694867"],"confidence":"High","gaps":["Direct FAK substrate relationship not established by substrate trapping","PTP-domain specificity determinants only partially mapped"]},{"year":2000,"claim":"Placed SHP-2 epistatically upstream of RAS and RhoA, defining its dual control of MAPK and small-GTPase signaling.","evidence":"Catalytically inactive SHP-2 blocking insulin/EGF Ras activation upstream of SOS; genetic and calpeptin perturbation elevating active RhoA","pmids":["10671568","11114521"],"confidence":"Medium","gaps":["Direct RhoA-pathway substrate not yet identified in these studies","Mechanism linking phosphatase activity to RAS-GTP loading unresolved"]},{"year":2001,"claim":"Identified PTPN11 gain-of-function mutations as the cause of Noonan syndrome, linking conformational activation to human disease.","evidence":"Mutation screening plus energetics-based structural analysis of N-SH2 mutants showing equilibrium shift to active state","pmids":["11704759"],"confidence":"High","gaps":["Direct measurement of mutant phosphatase activity not in this study","Downstream effector dysregulation not yet defined"]},{"year":2001,"claim":"Demonstrated SHP-2 as a target hijacked by a bacterial effector and required for PI3K/AKT and hematopoietic development.","evidence":"CagA complex formation activating SHP-2; SH2-domain-dependent PI3K p85 co-IP and Akt activation; RAG-2 blastocyst complementation showing no lymphoid development in Shp-2-null cells","pmids":["11743164","11593409","11159516"],"confidence":"High","gaps":["Precise mechanism by which SHP-2 promotes PI3K recruitment not fully defined","Relevant hematopoietic substrates not identified"]},{"year":2002,"claim":"Established GAB1/FRS-2 docking-protein recruitment as the route by which SHP-2 drives RAS activation and controls cell fate.","evidence":"Gab1(Y627F) and SHP-2(C459S) reducing active Ras with Ras rescue; FGF-induced SHP-2/FRS-2α complex required for ERK activation in myoblasts","pmids":["12370245","11997521"],"confidence":"High","gaps":["Direct substrate dephosphorylated to enable Ras activation not pinpointed","Erk-independent repression of myogenesis mechanistically unresolved"]},{"year":2003,"claim":"Identified STAT5A as a direct SHP-2 substrate and tied somatic PTPN11 mutations to leukemia through RAS.","evidence":"pY-Stat5A affinity purification and dephosphorylation kinetics in Shp-2-deficient cells; JMML mutation screening mutually exclusive with RAS/NF1 plus Ba/F3 growth-factor-independence","pmids":["12615921","14644997"],"confidence":"Medium","gaps":["JMML study showed negative ERK/Akt hyperactivation, leaving effector mechanism open","Leukemogenic substrate spectrum not defined"]},{"year":2004,"claim":"Connected SHP-2 conformational activation in disease mutants to sustained GAB1 binding and ERK output, and identified p190-B RhoGAP as a direct substrate linking SHP-2 to RhoA-dependent myogenesis.","evidence":"Noonan mutant phosphatase assays with GAB1-FF dominant negative; substrate-trapping mutants identifying p190-B RhoGAP with RhoA activity readout","pmids":["14974085","15169898"],"confidence":"High","gaps":["How dephosphorylation of a RhoGAP activates rather than inhibits RhoA mechanistically incomplete","Generalizability of GAB1-sustained ERK to all mutants untested"]},{"year":2005,"claim":"Revealed redox control of SHP-2 and context-dependent negative regulation of neurotrophin and TCR signaling.","evidence":"TCR-induced ROS oxidation of active-site cysteine with LAT/Gads/SLP-76 recruitment; Ca2+-enhanced SHP-2/TrkB association inhibiting BDNF signaling reversed by Shp2 deletion","pmids":["15933714","15650750"],"confidence":"Medium","gaps":["Single-lab redox findings without independent confirmation","Direct TrkB dephosphorylation versus indirect inhibition not distinguished"]},{"year":2006,"claim":"Defined phosphatase-independent functions of SHP-2 as a scaffold/chaperone, restraining innate immune TLR/TBK1 signaling and stabilizing Bcr-Abl.","evidence":"C-terminal domain binding to TBK1 with SHP-2-deficient cytokine analysis; Hsp90 co-IP and proteasome-dependent p210 Bcr-Abl degradation upon SHP-2 loss","pmids":["17157040","17003374"],"confidence":"High","gaps":["Structural basis of non-catalytic TBK1/Hsp90 interactions not defined","Balance between catalytic and scaffold roles in leukemia not quantified"]},{"year":2007,"claim":"Placed SHP-2 in cardiac progenitor maintenance and gastrulation movements through FGF/FRS-2, Src-family kinases, and RhoA.","evidence":"Xenopus cardiac progenitor assays with FRS-2 co-IP and FGF rescue; zebrafish morpholino knockdown rescued by active Fyn/Yes/RhoA, with patient mutants causing convergence-extension defects","pmids":["17928416","18159945"],"confidence":"High","gaps":["Direct substrates mediating C&E movements not identified","How both GOF and LOF mutants converge on the same defect mechanistically unresolved"]},{"year":2011,"claim":"Established tissue-specific roles of SHP-2 spanning tumor suppression, Schwann cell ErbB signaling, and mTOR-driven cardiomyopathy.","evidence":"Hepatocyte Shp2/Stat3 double KO abolishing HCC; conditional Schwann-cell KO with Src-inhibitor phenocopy; PDGFRα glioma model with PI3K rescue; cardiomyocyte Q510E transgenic rescued by rapamycin","pmids":["21575863","19805360","21393858","22058153"],"confidence":"High","gaps":["Context-dependent tumor suppressor versus oncogenic roles not mechanistically unified","Direct substrates in each tissue largely undefined"]},{"year":2012,"claim":"Extended SHP-2 function to actin/ROCK control of cardiac development, osteoclast fusion, and nutrient-sensing mTOR signaling.","evidence":"Xenopus Noonan mutant cardiac defects rescued by ROCK inhibition; osteoclast-specific KO osteopetrosis with RANKL/Nfatc1 defect; myoblast leucine-induced S6K1 activation via PLCβ4/Ca2+","pmids":["22278918","25593124","23129808"],"confidence":"Medium","gaps":["Direct substrate connecting SHP-2 to ROCK and Ca2+ pathways not identified","Leucine-sensing mechanism is single-lab"]},{"year":2013,"claim":"Broadened SHP-2 into vascular, endothelial, and intestinal barrier regulation and revealed negative-feedback loops controlling its recruitment.","evidence":"S-nitrosylation inhibiting neuronal SHP-2/ERK; ICAM-1/VE-cadherin interactions in endothelium; IEC-specific KO causing microbiota-dependent colitis; RSK phosphorylation of Gab2 limiting SHP-2 recruitment","pmids":["23382182","28701303","23530062","23401857"],"confidence":"Medium","gaps":["Several endothelial/feedback findings are single-lab","Direct substrates in barrier regulation not mapped"]},{"year":2014,"claim":"Provided direct structural evidence distinguishing Noonan (activating) from LEOPARD (inactivating) mutations.","evidence":"X-ray crystallography of wild-type and five disease-mutant SHP2 proteins","pmids":["24628801"],"confidence":"High","gaps":["Dynamics of the autoinhibitory switch not captured by static structures","Allosteric ligand-binding states not resolved here"]},{"year":2016,"claim":"Uncovered a cell-cycle role for SHP-2 at mitotic structures, linking GOF mutations to chromosomal instability via Plk1/c-Src.","evidence":"Immunofluorescence localization to kinetochore/centrosome/midbody and Plk1/c-Src kinase assays in Ptpn11 GOF knock-in MEFs","pmids":["26755576"],"confidence":"High","gaps":["Direct mitotic substrate of SHP-2 not identified","Single-study mitotic localization needs independent confirmation"]},{"year":2018,"claim":"Defined SHP-2 as a master regulator of the PDGFR phosphoproteome and a druggable node for KRAS-driven cancer, with a second allosteric site for inhibition.","evidence":"Quantitative phosphoproteomics with allosteric inhibitor SHP099; genetic Ptpn11 deletion in KRAS PDAC/NSCLC models with MEK-inhibitor synergy; crystallography of a second allosteric SHP244 site","pmids":["29514104","29808009","29304282"],"confidence":"High","gaps":["Direct versus indirect substrates within the phosphoproteome not fully separated","Resistance mechanisms to dual SHP2/MEK inhibition incompletely defined"]},{"year":2019,"claim":"Tied SHP-2 to immune-cell metabolism and inflammatory vascular dysfunction.","evidence":"NK-cell-specific KO with ERK and Seahorse metabolic defects; sepsis model showing ROS-inactivated SHP-2 interacting with MyD88 via Y257","pmids":["30926899","30905847"],"confidence":"Medium","gaps":["MyD88 interaction is single-lab via proximity ligation","Metabolic regulation mechanism downstream of ERK not detailed"]},{"year":2020,"claim":"Provided the biophysical basis for SHP-2 activation by inhibitory immune receptors through dual-ITSM bridging of PD-1.","evidence":"ITC, live-cell PD-1 dimerization, and enzymatic activation assays showing both SH2 domains engage two pY-ITSM-Y248 tails","pmids":["32184441"],"confidence":"High","gaps":["Downstream substrates dephosphorylated upon PD-1 engagement not defined here","Stoichiometry in physiological synapses not established"]},{"year":2022,"claim":"Connected the PD-1/SHP-2 module to myeloid differentiation and tumor immunity beyond T cells.","evidence":"Myeloid-specific SHP-2 or PD-1 KO with PD-1–SHP-2 recruitment to GM-CSF receptor and HOXA10/IRF8 phosphorylation analysis","pmids":["36581713"],"confidence":"High","gaps":["Whether HOXA10/IRF8 are direct SHP-2 substrates not established","Catalytic versus scaffold contribution to myeloid effect not separated"]},{"year":null,"claim":"How SHP-2's small set of validated direct substrates accounts for its simultaneous positive (RAS/MAPK, PI3K) and negative (JAK/STAT, RhoA, TLR) outputs across tissues remains the central unresolved question.","evidence":"","pmids":[],"confidence":"Medium","gaps":["Few direct catalytic substrates identified relative to breadth of phenotypes","Tissue-specific substrate selection mechanism unknown","Integration of catalytic and scaffold/chaperone functions not unified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[9,13,15,16,34,35]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[9,13,15,35]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[6,12,21,28]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[8,28]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[20,23]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[8,12,34]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[27]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[3,31]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[51]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,12,34,48,49]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,5,30,39,47]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[4,20,21,38,44]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[14,18,29,31,32]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[27]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[50]}],"complexes":["LAT-Gads-SLP-76 complex","PD-1:PD-1 dimer"],"partners":["GAB1","FRS-2","PD-1","JAK2","TBK1","GRB2","STAT5A","PDGFR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q06124","full_name":"Tyrosine-protein phosphatase non-receptor type 11","aliases":["Protein-tyrosine phosphatase 1D","PTP-1D","Protein-tyrosine phosphatase 2C","PTP-2C","SH-PTP2","SHP-2","Shp2","SH-PTP3"],"length_aa":593,"mass_kda":68.0,"function":"Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus (PubMed:10655584, PubMed:14739280, PubMed:18559669, PubMed:18829466, PubMed:26742426, PubMed:28074573, PubMed:32184441). Positively regulates MAPK signal transduction pathway (PubMed:28074573). Dephosphorylates GAB1, ARHGAP35 and EGFR (PubMed:28074573). Dephosphorylates ROCK2 at 'Tyr-722' resulting in stimulation of its RhoA binding activity (PubMed:18559669). Dephosphorylates CDC73 (PubMed:26742426). Dephosphorylates SOX9 on tyrosine residues, leading to inactivate SOX9 and promote ossification (By similarity). Dephosphorylates tyrosine-phosphorylated NEDD9/CAS-L (PubMed:19275884). Acts as an effector of PDCD1-mediated inhibition of T-cell response: recruited by phosphorylated PDCD1, mediating dephosphorylation of key T-cell receptor (TCR) proximal signaling molecules, leading to TCR signaling inhibition (PubMed:32184441)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/Q06124/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/PTPN11","classification":"Common Essential","n_dependent_lines":851,"n_total_lines":1208,"dependency_fraction":0.7044701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PTPN11","total_profiled":1310},"omim":[{"mim_id":"617998","title":"GRB2-ASSOCIATED REGULATOR OF MAPK1, SUBTYPE 1; GAREM1","url":"https://www.omim.org/entry/617998"},{"mim_id":"617573","title":"C-TYPE LECTIN DOMAIN FAMILY 12, MEMBER B; CLEC12B","url":"https://www.omim.org/entry/617573"},{"mim_id":"617079","title":"LONG INTERGENIC NONCODING RNA 673; LINC00673","url":"https://www.omim.org/entry/617079"},{"mim_id":"616804","title":"V-SET AND TRANSMEMBRANE DOMAINS-CONTAINING PROTEIN 1; VSTM1","url":"https://www.omim.org/entry/616804"},{"mim_id":"615879","title":"TATTON-BROWN-RAHMAN SYNDROME; TBRS","url":"https://www.omim.org/entry/615879"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoli rim","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Actin filaments","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PTPN11"},"hgnc":{"alias_symbol":["BPTP3","SH-PTP2","SHP-2","PTP2C","SHP2"],"prev_symbol":["NS1"]},"alphafold":{"accession":"Q06124","domains":[{"cath_id":"3.30.505.10","chopping":"12-100","consensus_level":"high","plddt":92.7442,"start":12,"end":100},{"cath_id":"3.30.505.10","chopping":"118-217","consensus_level":"high","plddt":86.3795,"start":118,"end":217},{"cath_id":"3.90.190.10","chopping":"253-526","consensus_level":"high","plddt":94.1534,"start":253,"end":526}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06124","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q06124-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q06124-F1-predicted_aligned_error_v6.png","plddt_mean":85.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PTPN11","jax_strain_url":"https://www.jax.org/strain/search?query=PTPN11"},"sequence":{"accession":"Q06124","fasta_url":"https://rest.uniprot.org/uniprotkb/Q06124.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q06124/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q06124"}},"corpus_meta":[{"pmid":"11704759","id":"PMC_11704759","title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.","date":"2001","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11704759","citation_count":1281,"is_preprint":false},{"pmid":"11743164","id":"PMC_11743164","title":"SHP-2 tyrosine phosphatase as an intracellular target of Helicobacter pylori CagA protein.","date":"2001","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/11743164","citation_count":828,"is_preprint":false},{"pmid":"10364425","id":"PMC_10364425","title":"Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells.","date":"1999","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/10364425","citation_count":431,"is_preprint":false},{"pmid":"9694867","id":"PMC_9694867","title":"Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9694867","citation_count":343,"is_preprint":false},{"pmid":"14644997","id":"PMC_14644997","title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14644997","citation_count":332,"is_preprint":false},{"pmid":"18286234","id":"PMC_18286234","title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer.","date":"2008","source":"Cancer metastasis reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18286234","citation_count":326,"is_preprint":false},{"pmid":"29808009","id":"PMC_29808009","title":"Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.","date":"2018","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29808009","citation_count":320,"is_preprint":false},{"pmid":"19290938","id":"PMC_19290938","title":"SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.","date":"2009","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/19290938","citation_count":304,"is_preprint":false},{"pmid":"10022928","id":"PMC_10022928","title":"Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10022928","citation_count":288,"is_preprint":false},{"pmid":"21575863","id":"PMC_21575863","title":"Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis.","date":"2011","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/21575863","citation_count":285,"is_preprint":false},{"pmid":"10579910","id":"PMC_10579910","title":"Shp-2 tyrosine phosphatase: signaling one cell or many.","date":"1999","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/10579910","citation_count":245,"is_preprint":false},{"pmid":"17227708","id":"PMC_17227708","title":"The role of Shp2 (PTPN11) in cancer.","date":"2007","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/17227708","citation_count":236,"is_preprint":false},{"pmid":"8063747","id":"PMC_8063747","title":"Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8063747","citation_count":231,"is_preprint":false},{"pmid":"17157040","id":"PMC_17157040","title":"SHP-2 phosphatase negatively regulates the TRIF adaptor protein-dependent type I interferon and proinflammatory cytokine production.","date":"2006","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/17157040","citation_count":207,"is_preprint":false},{"pmid":"26088100","id":"PMC_26088100","title":"Functions of Shp2 in cancer.","date":"2015","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26088100","citation_count":204,"is_preprint":false},{"pmid":"17647198","id":"PMC_17647198","title":"The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury.","date":"2007","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/17647198","citation_count":203,"is_preprint":false},{"pmid":"8514779","id":"PMC_8514779","title":"Tyrosyl phosphorylation and growth factor receptor association of the human corkscrew homologue, SH-PTP2.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8514779","citation_count":193,"is_preprint":false},{"pmid":"19622105","id":"PMC_19622105","title":"Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation.","date":"2009","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/19622105","citation_count":186,"is_preprint":false},{"pmid":"26341048","id":"PMC_26341048","title":"SHP2 sails from physiology to pathology.","date":"2015","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26341048","citation_count":182,"is_preprint":false},{"pmid":"14974085","id":"PMC_14974085","title":"Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/14974085","citation_count":159,"is_preprint":false},{"pmid":"32184441","id":"PMC_32184441","title":"Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32184441","citation_count":146,"is_preprint":false},{"pmid":"16084691","id":"PMC_16084691","title":"A SHPing tale: perspectives on the regulation of SHP-1 and SHP-2 tyrosine phosphatases by the C-terminal tail.","date":"2005","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/16084691","citation_count":144,"is_preprint":false},{"pmid":"11191350","id":"PMC_11191350","title":"The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions.","date":"2000","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/11191350","citation_count":138,"is_preprint":false},{"pmid":"11593409","id":"PMC_11593409","title":"The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11593409","citation_count":135,"is_preprint":false},{"pmid":"32437146","id":"PMC_32437146","title":"Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32437146","citation_count":132,"is_preprint":false},{"pmid":"29617671","id":"PMC_29617671","title":"Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29617671","citation_count":119,"is_preprint":false},{"pmid":"11114521","id":"PMC_11114521","title":"The protein tyrosine phosphatase Shp-2 regulates RhoA activity.","date":"2000","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/11114521","citation_count":116,"is_preprint":false},{"pmid":"12421673","id":"PMC_12421673","title":"Role of the SHP-2 tyrosine phosphatase in cytokine-induced signaling and cellular response.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12421673","citation_count":109,"is_preprint":false},{"pmid":"8995399","id":"PMC_8995399","title":"Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8995399","citation_count":109,"is_preprint":false},{"pmid":"10781410","id":"PMC_10781410","title":"Cytoplasmic protein tyrosine phosphatases SHP-1 and SHP-2: regulators of B cell signal transduction.","date":"2000","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10781410","citation_count":103,"is_preprint":false},{"pmid":"15834506","id":"PMC_15834506","title":"Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.","date":"2005","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15834506","citation_count":102,"is_preprint":false},{"pmid":"9418864","id":"PMC_9418864","title":"Structural determinants of SHP-2 function and specificity in Xenopus mesoderm induction.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9418864","citation_count":99,"is_preprint":false},{"pmid":"11159516","id":"PMC_11159516","title":"Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11159516","citation_count":97,"is_preprint":false},{"pmid":"29304282","id":"PMC_29304282","title":"Dual Allosteric Inhibition of SHP2 Phosphatase.","date":"2018","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/29304282","citation_count":95,"is_preprint":false},{"pmid":"15933714","id":"PMC_15933714","title":"Receptor-stimulated oxidation of SHP-2 promotes T-cell adhesion through SLP-76-ADAP.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15933714","citation_count":95,"is_preprint":false},{"pmid":"12615921","id":"PMC_12615921","title":"Identification of Shp-2 as a Stat5A phosphatase.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12615921","citation_count":94,"is_preprint":false},{"pmid":"14676626","id":"PMC_14676626","title":"SHP-2 and myeloid malignancies.","date":"2004","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/14676626","citation_count":93,"is_preprint":false},{"pmid":"19805360","id":"PMC_19805360","title":"The tyrosine phosphatase Shp2 (PTPN11) directs Neuregulin-1/ErbB signaling throughout Schwann cell development.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19805360","citation_count":92,"is_preprint":false},{"pmid":"9388260","id":"PMC_9388260","title":"The protein-tyrosine phosphatase SHP-2 associates with tyrosine-phosphorylated adhesion molecule PECAM-1 (CD31).","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9388260","citation_count":89,"is_preprint":false},{"pmid":"15040005","id":"PMC_15040005","title":"SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis.","date":"2004","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/15040005","citation_count":87,"is_preprint":false},{"pmid":"21291263","id":"PMC_21291263","title":"Substrate specificity of protein tyrosine phosphatases 1B, RPTPα, SHP-1, and SHP-2.","date":"2011","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21291263","citation_count":87,"is_preprint":false},{"pmid":"15169898","id":"PMC_15169898","title":"SHP-2 positively regulates myogenesis by coupling to the Rho GTPase signaling pathway.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/15169898","citation_count":81,"is_preprint":false},{"pmid":"18159945","id":"PMC_18159945","title":"Shp2 knockdown and Noonan/LEOPARD mutant Shp2-induced gastrulation defects.","date":"2007","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18159945","citation_count":78,"is_preprint":false},{"pmid":"12370245","id":"PMC_12370245","title":"Gab1 and SHP-2 promote Ras/MAPK regulation of epidermal growth and differentiation.","date":"2002","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/12370245","citation_count":75,"is_preprint":false},{"pmid":"21393858","id":"PMC_21393858","title":"SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans.","date":"2011","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/21393858","citation_count":75,"is_preprint":false},{"pmid":"36581713","id":"PMC_36581713","title":"SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses.","date":"2022","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36581713","citation_count":74,"is_preprint":false},{"pmid":"9693956","id":"PMC_9693956","title":"SHP-2, SH2-containing protein tyrosine phosphatase-2.","date":"1998","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/9693956","citation_count":74,"is_preprint":false},{"pmid":"18702480","id":"PMC_18702480","title":"2-Thiazolylimino/heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action.","date":"2008","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18702480","citation_count":69,"is_preprint":false},{"pmid":"16461457","id":"PMC_16461457","title":"Gain-of-function/Noonan syndrome SHP-2/Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling.","date":"2006","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/16461457","citation_count":66,"is_preprint":false},{"pmid":"18583343","id":"PMC_18583343","title":"Localization of PTP-1B, SHP-2, and Src exclusively in rat brain mitochondria and functional consequences.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18583343","citation_count":65,"is_preprint":false},{"pmid":"24628801","id":"PMC_24628801","title":"Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).","date":"2014","source":"BMC structural biology","url":"https://pubmed.ncbi.nlm.nih.gov/24628801","citation_count":63,"is_preprint":false},{"pmid":"35865095","id":"PMC_35865095","title":"Targeting macrophagic SHP2 for ameliorating osteoarthritis via TLR signaling.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35865095","citation_count":62,"is_preprint":false},{"pmid":"22058153","id":"PMC_22058153","title":"The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy by dysregulating mTOR signaling.","date":"2011","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22058153","citation_count":61,"is_preprint":false},{"pmid":"9379041","id":"PMC_9379041","title":"Syk-independent tyrosine phosphorylation and association of the protein tyrosine phosphatases SHP-1 and SHP-2 with the high affinity IgE receptor.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9379041","citation_count":59,"is_preprint":false},{"pmid":"11088001","id":"PMC_11088001","title":"Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2.","date":"2000","source":"Journal of physiology, Paris","url":"https://pubmed.ncbi.nlm.nih.gov/11088001","citation_count":59,"is_preprint":false},{"pmid":"7515062","id":"PMC_7515062","title":"Dephosphorylation of insulin receptor substrate 1 by the tyrosine phosphatase PTP2C.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7515062","citation_count":57,"is_preprint":false},{"pmid":"23382182","id":"PMC_23382182","title":"S-nitrosylated SHP-2 contributes to NMDA receptor-mediated excitotoxicity in acute ischemic stroke.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23382182","citation_count":55,"is_preprint":false},{"pmid":"28306669","id":"PMC_28306669","title":"Role of SHP2 in hematopoiesis and leukemogenesis.","date":"2017","source":"Current opinion in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/28306669","citation_count":53,"is_preprint":false},{"pmid":"29514104","id":"PMC_29514104","title":"Large-Scale Phosphoproteomics Reveals Shp-2 Phosphatase-Dependent Regulators of Pdgf Receptor Signaling.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29514104","citation_count":53,"is_preprint":false},{"pmid":"27894814","id":"PMC_27894814","title":"Tanshinone IIA induced cell death via miR30b-p53-PTPN11/SHP2 signaling pathway in human hepatocellular carcinoma cells.","date":"2016","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27894814","citation_count":53,"is_preprint":false},{"pmid":"22869052","id":"PMC_22869052","title":"Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis.","date":"2012","source":"Frontiers of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22869052","citation_count":47,"is_preprint":false},{"pmid":"31708921","id":"PMC_31708921","title":"SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31708921","citation_count":46,"is_preprint":false},{"pmid":"11997521","id":"PMC_11997521","title":"Role of SHP-2 in fibroblast growth factor receptor-mediated suppression of myogenesis in C2C12 myoblasts.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11997521","citation_count":45,"is_preprint":false},{"pmid":"18827006","id":"PMC_18827006","title":"SHP-2 is a novel target of Abl kinases during cell proliferation.","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18827006","citation_count":42,"is_preprint":false},{"pmid":"30398108","id":"PMC_30398108","title":"The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.","date":"2018","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/30398108","citation_count":41,"is_preprint":false},{"pmid":"26755576","id":"PMC_26755576","title":"Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26755576","citation_count":40,"is_preprint":false},{"pmid":"19427850","id":"PMC_19427850","title":"The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.","date":"2009","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19427850","citation_count":39,"is_preprint":false},{"pmid":"30926899","id":"PMC_30926899","title":"Shp-2 is critical for ERK and metabolic engagement downstream of IL-15 receptor in NK cells.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/30926899","citation_count":38,"is_preprint":false},{"pmid":"19915046","id":"PMC_19915046","title":"SHP-2 expression negatively regulates NK cell function.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19915046","citation_count":37,"is_preprint":false},{"pmid":"22681964","id":"PMC_22681964","title":"PTPN11-associated mutations in the heart: has LEOPARD changed Its RASpots?","date":"2011","source":"Trends in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22681964","citation_count":37,"is_preprint":false},{"pmid":"10098842","id":"PMC_10098842","title":"Tyrosine phosphorylation and association of BIT with SHP-2 induced by neurotrophins.","date":"1999","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10098842","citation_count":37,"is_preprint":false},{"pmid":"23530062","id":"PMC_23530062","title":"Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23530062","citation_count":37,"is_preprint":false},{"pmid":"23825065","id":"PMC_23825065","title":"Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/23825065","citation_count":36,"is_preprint":false},{"pmid":"22878065","id":"PMC_22878065","title":"Shp-2 regulates the TrkB receptor activity in the retinal ganglion cells under glaucomatous stress.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22878065","citation_count":36,"is_preprint":false},{"pmid":"10671568","id":"PMC_10671568","title":"Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-Jun NH(2)-terminal kinase.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10671568","citation_count":35,"is_preprint":false},{"pmid":"15650750","id":"PMC_15650750","title":"Tyrosine phosphatase SHP-2 is a mediator of activity-dependent neuronal excitotoxicity.","date":"2005","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/15650750","citation_count":33,"is_preprint":false},{"pmid":"37304233","id":"PMC_37304233","title":"Macrophage-derived SHP-2 inhibits the metastasis of colorectal cancer via Tie2-PI3K signals.","date":"2023","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/37304233","citation_count":32,"is_preprint":false},{"pmid":"24439672","id":"PMC_24439672","title":"Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer.","date":"2013","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/24439672","citation_count":32,"is_preprint":false},{"pmid":"17003374","id":"PMC_17003374","title":"SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17003374","citation_count":32,"is_preprint":false},{"pmid":"24088816","id":"PMC_24088816","title":"Loss of SHP-2 activity in CD4+ T cells promotes melanoma progression and metastasis.","date":"2013","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/24088816","citation_count":32,"is_preprint":false},{"pmid":"17928416","id":"PMC_17928416","title":"SHP-2 is required for the maintenance of cardiac progenitors.","date":"2007","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/17928416","citation_count":30,"is_preprint":false},{"pmid":"25593124","id":"PMC_25593124","title":"SHP2 regulates osteoclastogenesis by promoting preosteoclast fusion.","date":"2015","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25593124","citation_count":29,"is_preprint":false},{"pmid":"20512931","id":"PMC_20512931","title":"Integrin beta4 attenuates SHP-2 and MAPK signaling and reduces human lung endothelial inflammatory responses.","date":"2010","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20512931","citation_count":29,"is_preprint":false},{"pmid":"27709270","id":"PMC_27709270","title":"SHP-2 phosphatase controls aryl hydrocarbon receptor-mediated ER stress response in mast cells.","date":"2016","source":"Archives of toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/27709270","citation_count":28,"is_preprint":false},{"pmid":"23401857","id":"PMC_23401857","title":"Gab2 phosphorylation by RSK inhibits Shp2 recruitment and cell motility.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23401857","citation_count":28,"is_preprint":false},{"pmid":"12769687","id":"PMC_12769687","title":"Gab1, SHP-2 and other novel regulators of Ras: targets for anticancer drug discovery?","date":"2003","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/12769687","citation_count":26,"is_preprint":false},{"pmid":"35034964","id":"PMC_35034964","title":"SKAP2 suppresses inflammation-mediated tumorigenesis by regulating SHP-1 and SHP-2.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35034964","citation_count":26,"is_preprint":false},{"pmid":"31197031","id":"PMC_31197031","title":"Pathogenic variants of DYNC2H1, KIAA0556, and PTPN11 associated with hypothalamic hamartoma.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31197031","citation_count":26,"is_preprint":false},{"pmid":"35575058","id":"PMC_35575058","title":"Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery.","date":"2022","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/35575058","citation_count":25,"is_preprint":false},{"pmid":"23129808","id":"PMC_23129808","title":"Novel role for SHP-2 in nutrient-responsive control of S6 kinase 1 signaling.","date":"2012","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23129808","citation_count":25,"is_preprint":false},{"pmid":"19160029","id":"PMC_19160029","title":"Polymorphisms of PTPN11 coding SHP-2 as biomarkers for ulcerative colitis susceptibility in the Japanese population.","date":"2009","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19160029","citation_count":25,"is_preprint":false},{"pmid":"30905847","id":"PMC_30905847","title":"Inactivation of the tyrosine phosphatase SHP-2 drives vascular dysfunction in Sepsis.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30905847","citation_count":25,"is_preprint":false},{"pmid":"22278918","id":"PMC_22278918","title":"SHP-2 acts via ROCK to regulate the cardiac actin cytoskeleton.","date":"2012","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22278918","citation_count":25,"is_preprint":false},{"pmid":"28174704","id":"PMC_28174704","title":"New and Unexpected Biological Functions for the Src-Homology 2 Domain-Containing Phosphatase SHP-2 in the Gastrointestinal Tract.","date":"2015","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28174704","citation_count":24,"is_preprint":false},{"pmid":"31635340","id":"PMC_31635340","title":"PTPN11 (SHP2) Is Indispensable for Growth Factors and Cytokine Signal Transduction During Bovine Oocyte Maturation and Blastocyst Development.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31635340","citation_count":24,"is_preprint":false},{"pmid":"11493654","id":"PMC_11493654","title":"SHP-2 complex formation with the SHP-2 substrate-1 during C2C12 myogenesis.","date":"2001","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/11493654","citation_count":23,"is_preprint":false},{"pmid":"9931295","id":"PMC_9931295","title":"Tyrosine phosphatase SHP-2 dephosphorylates the platelet-derived growth factor receptor but enhances its downstream signalling.","date":"1999","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9931295","citation_count":23,"is_preprint":false},{"pmid":"24736444","id":"PMC_24736444","title":"Distinct and overlapping functions of ptpn11 genes in Zebrafish development.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24736444","citation_count":23,"is_preprint":false},{"pmid":"35503226","id":"PMC_35503226","title":"Targeting SHP2 phosphatase in hematological malignancies.","date":"2022","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/35503226","citation_count":22,"is_preprint":false},{"pmid":"28701303","id":"PMC_28701303","title":"Endothelial cell SHP-2 negatively regulates neutrophil adhesion and promotes transmigration by enhancing ICAM-1-VE-cadherin interaction.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28701303","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48886,"output_tokens":14437,"usd":0.181607,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":26662,"output_tokens":7371,"usd":0.158793,"stage2_stop_reason":"end_turn"},"total_usd":0.3404,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Missense mutations in PTPN11 (encoding SHP-2) cause Noonan syndrome. All mutations cluster in interacting portions of the N-SH2 domain and the phosphotyrosine phosphatase (PTP) domain involved in switching the protein between inactive and active conformations. Energetics-based structural analysis of two N-SH2 mutants indicates a significant shift of equilibrium favoring the active conformation, implying gain-of-function changes with excessive SHP-2 activity.\",\n      \"method\": \"Mutational analysis, energetics-based structural analysis of N-SH2 domain mutants\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structural and energetics analysis combined with large-scale mutation screening; foundational paper replicated extensively\",\n      \"pmids\": [\"11704759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"H. pylori CagA protein is injected into host cells, undergoes tyrosine phosphorylation, and forms a physical complex with SHP-2 in a phosphorylation-dependent manner, stimulating SHP-2 phosphatase activity. Disruption of the CagA-SHP-2 complex abolished CagA-dependent cellular (growth factor-like) response, and the CagA effect was reproduced by constitutively active SHP-2.\",\n      \"method\": \"Co-immunoprecipitation, phosphatase activity assay, dominant-active SHP-2 expression, disruption of complex\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, phosphatase assay, functional rescue with constitutively active SHP-2; widely replicated\",\n      \"pmids\": [\"11743164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SHP-2 and ERK signaling downstream of gp130 suppresses mouse ES cell self-renewal. A gp130 receptor mutant (Y118F) that fails to engage SHP-2 and cannot activate ERKs supports ES cell self-renewal at 100-fold lower cytokine concentrations with sustained STAT3 activation. MEK inhibitor PD098059 also enhanced undifferentiated ES cell growth, indicating that ERK activation actively impairs self-renewal.\",\n      \"method\": \"Chimeric receptor mutagenesis (Y118F), MEK inhibitor (PD098059), ES cell self-renewal assay, STAT3 activation measurement\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via receptor mutagenesis plus pharmacological inhibitor, multiple orthogonal methods\",\n      \"pmids\": [\"10364425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Shp-2 is required for cell spreading, migration, and regulation of focal adhesion architecture. Fibroblasts lacking functional Shp-2 show impaired spreading and migration on fibronectin, increased focal adhesions, and condensed F-actin. FAK dephosphorylation was significantly reduced in Shp-2 mutant cells in suspension, and regulated association of Src SH2 domain with FAK and paxillin during cell attachment/detachment on fibronectin was disrupted.\",\n      \"method\": \"Genetic knockout (Shp-2 mutant fibroblasts), fibronectin adhesion/migration assays, biochemical analysis of FAK phosphorylation, Src-FAK-paxillin co-IP\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with defined cellular phenotype plus biochemical pathway analysis; replicated by other labs\",\n      \"pmids\": [\"9694867\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Shp-2 functions as a negative regulator of the interferon-stimulated JAK/STAT pathway. Shp-2-deficient fibroblasts show augmented suppression of cell viability and markedly elevated STAT1 tyrosine phosphorylation and DNA binding upon IFN-α or IFN-γ stimulation. Reintroduction of wild-type Shp-2 reversed hypersensitivity to IFNs and excessive STAT activation.\",\n      \"method\": \"Shp-2 knockout fibroblasts, EMSA (hSIE probe), Western blot for STAT1 phosphorylation, rescue with wild-type Shp-2 re-expression\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic loss-of-function plus functional rescue, multiple orthogonal methods in single study\",\n      \"pmids\": [\"10022928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Somatic PTPN11 mutations occur in juvenile myelomonocytic leukemia (JMML) and are largely mutually exclusive with RAS and NF1 mutations, suggesting mutant SHP-2 proteins deregulate myeloid growth through Ras. Ba/F3 cells expressing leukemia-associated SHP-2 proteins showed enhanced growth factor-independent survival.\",\n      \"method\": \"Mutation screening, Ba/F3 cell growth factor-independence assay, biochemical analysis of ERK/Akt\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutation screening plus functional cell assay; single study, ERK/Akt hyperactivation was negative\",\n      \"pmids\": [\"14644997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Noonan syndrome-associated SHP-2/PTPN11 mutants have increased basal phosphatase activity and, after EGF stimulation, show prolonged binding to GAB1 and sustained ERK2/MAPK1 activation. Coexpression of GAB1-FF (lacking SHP-2 binding motifs) blocked EGF-mediated increase in SHP-2 phosphatase activity and dramatically reduced ERK2 activation.\",\n      \"method\": \"Phosphatase activity assays, co-immunoprecipitation of GAB1-SHP-2, ERK2 activation (Western blot), GAB1-FF dominant-negative expression\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (phosphatase assay, co-IP, dominant-negative rescue) in single study\",\n      \"pmids\": [\"14974085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Hepatocyte-specific deletion of Shp2 promotes inflammatory signaling through the Stat3 pathway, leading to hepatic inflammation/necrosis, regenerative hyperplasia, and tumor development in aged mice. Concurrent deletion of Shp2 and Stat3 abolished DEN-induced hepatocellular carcinoma, establishing a Stat3-dependent tumor-suppressor function for Shp2 in liver.\",\n      \"method\": \"Hepatocyte-specific conditional knockout (Cre-lox), genetic epistasis (double Shp2/Stat3 KO), DEN-induced HCC model\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific KO with genetic epistasis rescue, rigorous in vivo model\",\n      \"pmids\": [\"21575863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"SH-PTP2 (SHP-2) associates in vivo with ligand-activated EGF and PDGF receptors via its N-terminal SH2 domain. SH-PTP2 itself becomes tyrosyl phosphorylated upon growth factor activation.\",\n      \"method\": \"Co-immunoprecipitation from cells, SH2 domain direct binding assay, phosphotyrosine Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct binding assay plus in vivo co-IP; widely replicated foundational finding\",\n      \"pmids\": [\"8514779\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"PTP2C (SHP-2) rapidly dephosphorylates tyrosine-phosphorylated IRS-1. The SH2 domains of PTP2C enhance its activity toward IRS-1 (dephosphorylation by the SH2 domain-deleted form was ~3-fold slower), suggesting that SH2-domain binding to pY-IRS-1 allosterically activates the phosphatase toward this substrate.\",\n      \"method\": \"In vitro phosphatase assay with recombinant IRS-1 and truncated PTP2C, comparison of full-length vs. SH2-deleted enzyme\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstituted phosphatase assay with defined substrates and domain-deletion variants\",\n      \"pmids\": [\"7515062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SHP-2 is tyrosine-phosphorylated by JAK1 and JAK2 (but not JAK3) and associates with them. The SH2 domains of SHP-2 are not essential for JAK binding; instead, amino acids 232–272 in SHP-2 mediate the interaction. JAKs phosphorylate SHP-2 on Y304 and Y327, and phosphorylated SHP-2 associates with the adaptor Grb2. The N-terminus of JAK2 (not its kinase-like domain) is required for association with SHP-2.\",\n      \"method\": \"COS-1 cell co-transfection, co-immunoprecipitation, domain-deletion/point-mutation mapping, kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic domain-deletion and phosphosite mutagenesis with co-IP; multiple orthogonal methods\",\n      \"pmids\": [\"8995399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Shp-2 acts upstream of RhoA to regulate its activity. Perturbation of Shp-2 activity by genetic manipulations (including catalytically inactive mutants and deletion) results in raised levels of active RhoA. Calpeptin, which interferes with Shp-2 catalytic activity in vitro, also elevates active RhoA in vivo.\",\n      \"method\": \"Genetic manipulation of Shp-2 (dominant negative and null), RhoA activity assay (GTP-loading), in vitro calpeptin inhibition of Shp-2\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic strategies plus in vitro biochemical assay, epistatic placement of Shp-2 upstream of RhoA\",\n      \"pmids\": [\"11114521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"SHP-2 is required for mediating PI3K/Akt activation by growth factors (EGF, PDGF, IGF). Deletion of the N-terminal SH2 domain of SHP-2 severely impaired PDGF- and IGF-induced Akt phosphorylation. EGF stimulation induced co-immunoprecipitation of the p85 subunit of PI3K with SHP-2. Ectopic wild-type SHP-2 expression elevated EGF-induced Akt phosphorylation in an N-terminal SH2-domain-dependent manner.\",\n      \"method\": \"SHP-2 domain-deletion (exon 3) cell lines, co-immunoprecipitation of PI3K p85 with SHP-2, Akt phosphorylation (Western blot), lipid kinase assay, reconstitution in SHP-2-/- fibroblasts\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cell models, co-IP, lipid kinase assay, domain-deletion mutagenesis\",\n      \"pmids\": [\"11593409\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Shp-2 is a Stat5A phosphatase. Shp-2 (but not Shp-1) specifically interacted with tyrosine-phosphorylated Stat5A in vivo. Shp-2 accelerated Stat5A dephosphorylation, and dephosphorylation of Stat5A was dramatically delayed in Shp-2-deficient cells.\",\n      \"method\": \"Affinity purification using pY-Stat5A peptides, co-immunoprecipitation, dephosphorylation kinetics assay, Shp-2-deficient cell comparison\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — biochemical substrate identification plus genetic loss-of-function confirmation\",\n      \"pmids\": [\"12615921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Both SH2 domains and the PTP catalytic domain of SHP-2 are required for normal function in Xenopus mesoderm induction. The N-terminal SH2 domain is absolutely required, the C-terminal SH2 contributes to wild-type function, whereas C-terminal tyrosyl phosphorylation sites and proline-rich region are dispensable. SHP-2/SHP-1 chimera studies revealed that substantial specificity resides in the PTP domain itself.\",\n      \"method\": \"Xenopus mesoderm induction assay, domain-deletion and chimera mutagenesis (SHP-2/SHP-1 chimeras), functional readout (mesoderm induction, gastrulation)\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — systematic domain mutagenesis with in vivo functional readout, multiple mutants tested\",\n      \"pmids\": [\"9418864\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SHP-2 positively regulates myogenesis by dephosphorylating p190-B RhoGAP, which promotes RhoA activation. SHP-2 substrate-trapping mutants identified p190-B RhoGAP as a direct SHP-2 substrate. During myogenesis, p190-B RhoGAP tyrosyl dephosphorylation correlated with SHP-2 phosphatase activation; a catalytically inactive SHP-2 mutant inhibited p190-B RhoGAP dephosphorylation, RhoA activity, and myogenesis.\",\n      \"method\": \"SHP-2 substrate-trapping mutants, co-immunoprecipitation, RhoA activity assay, catalytically inactive SHP-2 overexpression, RNAi knockdown\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — substrate trapping identifies direct substrate, multiple orthogonal approaches, epistatic placement\",\n      \"pmids\": [\"15169898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"SHP-2 dephosphorylates the PDGF receptor, yet enhances PDGF-induced MAP kinase pathway activation. Catalytically active SHP-2 decreased PDGF receptor tyrosine phosphorylation while enhancing MAP kinase activation; catalytically inactive SHP-2 had the opposite effects.\",\n      \"method\": \"Co-expression of active/inactive SHP-2 with PDGF receptor in HEK293 cells, receptor phosphorylation assay, MAP kinase activation assay\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-expression with active/inactive mutants, single lab, two orthogonal readouts\",\n      \"pmids\": [\"9931295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Gain-of-function SHP-2 mutants (Noonan syndrome-associated) enhance FGF-2-mediated Ca2+ oscillations in fibroblasts and spontaneous Ca2+ oscillations in cardiomyocytes. Enhanced Ca2+ oscillation frequency correlates with reduced nuclear translocation and transcriptional activity of NFAT, dependent on SHP-2 phosphatase activity.\",\n      \"method\": \"Ca2+ oscillation imaging, NFAT nuclear translocation assay, gain-of-function SHP-2 mutant expression in fibroblasts and cardiomyocytes\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell Ca2+ imaging plus transcription factor localization assay, single lab\",\n      \"pmids\": [\"16461457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Shp-2 is an essential component of Neuregulin-1/ErbB signaling in Schwann cells. Conditional mutation of Shp2 in neural crest cells/Schwann cells abolished Nrg1-evoked proliferation and migration and altered Nrg1-dependent intracellular signaling. Pharmacological inhibition of Src family kinases mimicked all effects, implicating Src as a primary Shp-2 target during Nrg1 signaling.\",\n      \"method\": \"Conditional knockout (neural crest/Schwann cell-specific), Schwann cell proliferation/migration assays, Src family kinase inhibitor phenocopy\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific genetic KO plus pharmacological epistasis, multiple orthogonal methods\",\n      \"pmids\": [\"19805360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"SHP-2 (but not SHP-1) associates with tyrosine-phosphorylated PECAM-1 (CD31) via its SH2 domains following integrin or immune receptor activation. SHP-2 SH2 domain fusion protein directly bound phosphorylated PECAM-1, and SHP-2 dephosphorylated PECAM-1 in immune precipitate phosphatase assays.\",\n      \"method\": \"Co-immunoprecipitation, SH2 domain GST-pulldown, direct binding to pY-PECAM-1, immune-complex phosphatase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus direct binding plus in vitro phosphatase assay, single lab\",\n      \"pmids\": [\"9388260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TCR activation induces ROS-dependent transient inactivation (oxidation) of SHP-2's active site cysteine. SHP-2 is recruited to the LAT-Gads-SLP-76 complex and directly regulates phosphorylation of Vav1 and ADAP. ADAP association with SLP-76 is regulated by SHP-2 in a redox-dependent manner, promoting T-cell adhesion through integrin activation.\",\n      \"method\": \"Oxidation assay of active-site cysteine, co-immunoprecipitation with LAT/Gads/SLP-76 complex, phosphorylation analysis of Vav1/ADAP, T-cell adhesion assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct redox assay plus co-IP plus functional adhesion readout, single lab\",\n      \"pmids\": [\"15933714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SHP-2 negatively regulates TRIF-dependent TLR signaling by directly binding TANK-binding kinase 1 (TBK1) via its C-terminal domain (interaction with TBK1 kinase domain), independent of phosphatase activity. SHP-2 deficiency increased TBK1-activated IFN-β and TNF-α expression. SHP-2 also inhibited poly(I:C)-induced MAP kinase pathway activation.\",\n      \"method\": \"Co-immunoprecipitation of SHP-2 C-terminal domain with TBK1, SHP-2-deficient cell analysis, TBK1 knockdown epistasis, cytokine measurement\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — domain mapping of interaction, genetic KO, epistasis (TBK1 KD), phosphatase-independent mechanism established by multiple methods\",\n      \"pmids\": [\"17157040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SHP-2 (PTPN11) is required for PDGFRA-driven gliomagenesis in Ink4a/Arf-deficient cells. Abrogation of SHP-2-binding motifs in PDGFRα or SHP-2 shRNA knockdown disrupted PI3K interaction with PDGFRα, suppressed AKT/mTOR activation, and impaired tumorigenesis. Activated PI3K mutant expression rescued the effect of SHP-2 inhibition, placing SHP-2 upstream of PI3K in this pathway.\",\n      \"method\": \"Receptor mutagenesis (SHP-2 binding site ablation), shRNA knockdown, pharmacological SHP-2 inhibition, activated PI3K rescue, in vivo glioma model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — receptor mutagenesis plus genetic KD plus genetic rescue, multiple orthogonal methods in vivo and in vitro\",\n      \"pmids\": [\"21393858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"S-nitrosylation of SHP-2 at its active-site cysteine by NO (forming SNO-SHP-2) inhibits its phosphatase activity in neurons. NMDA exposure and transient focal cerebral ischemia increased SNO-SHP-2 levels, blocking downstream ERK1/2 neuroprotective signaling and increasing susceptibility to NMDA receptor-mediated excitotoxicity.\",\n      \"method\": \"S-nitrosylation assay (biotin-switch), phosphatase activity assay of SNO-SHP-2, NMDA treatment in vitro, focal ischemia model in vivo, ERK1/2 activation assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct PTM identification with biochemical activity assay, in vitro and in vivo models\",\n      \"pmids\": [\"23382182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Tyrosine phosphatase SHP-2 negatively regulates TrkB receptor activity in cerebellar neurons under conditions of excessive calcium influx. Calcium influx (via L-type channels or glutamate receptors) enhanced association of Shp-2 with TrkB receptors, inhibiting BDNF-induced TrkB autophosphorylation and downstream Ras/Erk/Akt activation. Deletion of the Shp2 gene reversed inhibition of TrkB and increased neuronal survival.\",\n      \"method\": \"Shp-2 gene deletion in neuronal cultures, co-immunoprecipitation of Shp-2 with TrkB, TrkB autophosphorylation assay, neuronal survival assay with depolarization/glutamate\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO plus co-IP plus functional rescue, multiple orthogonal methods\",\n      \"pmids\": [\"15650750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SHP-2 is a novel substrate of Abl family kinases during growth factor-mediated proliferation. Endogenous Abl kinases phosphorylate SHP-2 on Y580, inducing sustained ERK activation. Abl kinases also indirectly mediate phosphorylation of SHP-2 on Y63 and Y279; phosphorylation of Y279 downregulates sustained ERK activation and proliferation, constituting a negative-feedback mechanism.\",\n      \"method\": \"Pharmacological Abl inhibition (imatinib), RNAi knockdown, site-directed mutagenesis of SHP-2 phosphorylation sites, ERK activation assay, proliferation (G1-to-S) assay\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibitor and RNAi plus phosphosite mutagenesis, single lab\",\n      \"pmids\": [\"18827006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SHP-2 is required for hematopoietic cell transformation by Bcr-Abl. SHP-2 interacts with Hsp90, and loss of SHP-2 leads to proteasome-mediated degradation of p210 Bcr-Abl independently of SHP-2's catalytic activity. Inhibition of SHP-2 enzymatic activity (without destabilizing p210) also enhanced apoptosis, indicating a dual role (chaperone and signaling) of SHP-2 in Bcr-Abl leukemogenesis.\",\n      \"method\": \"Shp-2 conditional deletion in hematopoietic cells, leukemia transplantation model, Hsp90 co-immunoprecipitation, proteasome inhibitor rescue, antisense/siRNA knockdown, catalytically inactive SHP-2 overexpression\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with in vivo model, co-IP with Hsp90, pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"17003374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Gain-of-function Ptpn11 mutations disturb mitosis and cytokinesis, causing chromosomal instability. Shp-2 localizes to the kinetochore, centrosome, spindle midzone, and midbody. GOF mutant Shp-2 hyperactivates Polo-like kinase 1 (Plk1) by enhancing c-Src kinase-mediated tyrosine phosphorylation of Plk1.\",\n      \"method\": \"Immunofluorescence localization of Shp-2 to mitotic structures, Plk1 kinase assay, c-Src kinase assay, MEFs from Ptpn11 GOF knock-in mice, chromosomal instability analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct localization plus kinase activity assay plus genetic model, multiple orthogonal methods\",\n      \"pmids\": [\"26755576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SHP-2 bridges two PD-1 molecules by simultaneously engaging phosphorylated ITSM-Y248 residues on two PD-1 cytoplasmic tails via its N-SH2 and C-SH2 domains, forming a PD-1:PD-1 dimer. This dual engagement induces robust SHP-2 enzymatic activation. The interaction and activation depend exclusively on ITSM-Y248.\",\n      \"method\": \"Isothermal titration calorimetry (ITC), PD-1 dimerization in live cells, SHP-2 enzymatic activation assay with ITSM phosphopeptides, site-directed mutagenesis\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ITC biophysical measurement plus live-cell interaction assay plus enzymatic activation assay, multiple orthogonal methods\",\n      \"pmids\": [\"32184441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In zebrafish, Shp-2 is required for convergence and extension cell movements during gastrulation. Shp-2 knockdown-induced defects were rescued by active Fyn, active Yes (Src family kinases), and active RhoA, placing Src family kinases and RhoA downstream of Shp-2 in this process. Noonan syndrome Shp-2 mutants are activated (gain-of-function) while LEOPARD syndrome mutants lack catalytic activity; both cause convergence/extension defects.\",\n      \"method\": \"Morpholino knockdown in zebrafish, cell tracing experiments, epistatic rescue with constitutively active Fyn/Yes/RhoA, in situ hybridization, expression of patient-derived mutants\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — morpholino KD plus multiple epistatic rescues, cell tracing, multiple orthogonal approaches\",\n      \"pmids\": [\"18159945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The PTPN11 loss-of-function mutation Q510E-Shp2 causes hypertrophic cardiomyopathy (HCM) by dysregulating mTOR signaling. Cardiomyocyte-specific overexpression of Q510E-Shp2 hyperactivated Akt/mTOR signaling, and rapamycin treatment rescued the HCM phenotype both prophylactically and therapeutically. Normal Shp-2 controls cardiomyocyte size by regulating Akt/mTOR.\",\n      \"method\": \"Cardiomyocyte-specific transgenic mouse model, Akt/mTOR phosphorylation (Western blot), rapamycin rescue, echocardiography, histology\",\n      \"journal\": \"American journal of physiology. Heart and circulatory physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain-of-function mouse model plus pharmacological rescue, functional cardiac phenotyping\",\n      \"pmids\": [\"22058153\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"In Xenopus, SHP-2 regulates the cardiac actin cytoskeleton via ROCK. Noonan syndrome SHP-2 mutations cause cardiac cell cycle arrest in M-phase, failure of cardiomyocyte progenitors to incorporate into the developing heart, and defective actin fiber formation and polarity. ROCK inhibition rescued these cardiac defects, demonstrating that SHP-2(N308D) signals through ROCK to regulate the cardiac actin cytoskeleton.\",\n      \"method\": \"Xenopus cardiac development model, Noonan/JMML mutant SHP-2 expression, ROCK inhibitor rescue, F-actin staining, cardiac cell cycle analysis\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain-of-function plus pharmacological epistasis (ROCK inhibitor rescue), multiple cellular readouts\",\n      \"pmids\": [\"22278918\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In Xenopus, SHP-2 activity is required for maintenance and survival of proliferating cardiac progenitor cells. SHP-2 is phosphorylated on Y542/Y580 and binds to FRS-2, placing SHP-2 in the FGF pathway during early embryonic heart development. FGF signaling inhibition mimics SHP-2 inhibition effects, and constitutively active/Noonan-associated SHP-2 rescues FGF signaling inhibition.\",\n      \"method\": \"Xenopus cardiac progenitor assay, SHP-2 phosphorylation analysis (Y542/Y580), FRS-2 co-immunoprecipitation, FGF inhibitor phenocopy, constitutively active SHP-2 rescue\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP binding, phosphorylation mapping, FGF inhibitor epistasis, rescue experiment\",\n      \"pmids\": [\"17928416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Shp-2 is required for lymphoid and hematopoietic cell development across all blood cell lineages. Shp-2-/- ES cells in RAG-2-deficient blastocyst complementation yielded no mature T or B cells, nor precursor lymphocytes. Shp-1 deficiency (me(v)/me(v)) partially rescued Shp-2-/- hematopoietic defects, demonstrating antagonistic roles for Shp-1 and Shp-2 in hematopoiesis via the same signaling pathway(s).\",\n      \"method\": \"RAG-2-deficient blastocyst complementation, double Shp-2-/-/mev/mev mutant analysis, yolk sac hematopoiesis quantification\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in vivo with blastocyst complementation and double mutant analysis\",\n      \"pmids\": [\"11159516\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Large-scale phosphoproteomics identified Shp-2 as the master regulator of PDGF receptor (Pdgfr) pTyr signaling. Allosteric Shp-2 inhibition revealed global regulation of the Pdgf-dependent tyrosine phosphoproteome. Key Shp-2-dependent targets include Rasa1 and Cortactin (increased pTyr upon Shp-2 inhibition) and Gab1 and Erk1/2 (decreased pTyr). Shp-2 inhibition significantly impaired PDGF-stimulated cell migration.\",\n      \"method\": \"Quantitative phosphoproteomics (>40,000 phosphorylation sites), allosteric Shp-2 inhibitor (SHP099), cell migration assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — large-scale unbiased substrate identification plus functional cell migration assay, comprehensive coverage\",\n      \"pmids\": [\"29514104\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Substrate specificity profiling by combinatorial peptide library screening established that SHP-2 shares similar but narrower substrate specificities with SHP-1: both strongly prefer acidic and aromatic hydrophobic amino acids flanking the pY residue, with preference for ≥2 acidic residues N-terminal and ≥1 acidic residue C-terminal to pY, and exclusion of basic residues. The in vitro specificity profile agreed with in vivo dephosphorylation patterns of known SHP-2 substrates.\",\n      \"method\": \"On-bead screening of combinatorial phosphotyrosyl peptide libraries, solution-phase kinetic analysis of individually synthesized pY peptides\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstituted assay with combinatorial library screening and kinetic validation\",\n      \"pmids\": [\"21291263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SHP-2 regulates osteoclastogenesis by promoting preosteoclast fusion, required for formation of giant multinucleated osteoclasts. OC-specific Shp2 knockout mice are osteopetrotic. Shp-2 is required for RANKL-induced upregulation of Nfatc1 (master transcription factor for terminal OC differentiation). Shp-2 deletion had minimal effect on M-CSF-dependent OC precursor survival/proliferation.\",\n      \"method\": \"Osteoclast-specific conditional Shp2 knockout, microCT bone analysis, RANKL-induced Nfatc1 expression assay, cell fusion assay, pharmacological Shp2 inhibition\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific KO with comprehensive bone phenotyping plus molecular pathway analysis\",\n      \"pmids\": [\"25593124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SHP-2 is required for leucine-induced S6K1 activation in skeletal myoblasts via mobilization of intracellular Ca2+ in an IP3-dependent manner. SHP-2 acts upstream of phospholipase C β4 to generate nutrient-induced Ca2+ release and S6K1 phosphorylation. SHP-2-deficient myoblasts have impaired leucine sensing, defective autophagy, and reduced myoblast size.\",\n      \"method\": \"SHP-2 knockout/overexpression in myoblasts, S6K1 phosphorylation assay, Ca2+ mobilization assay, IP3 measurement, PLC β4 epistasis, autophagy assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO plus multiple biochemical readouts, single lab\",\n      \"pmids\": [\"23129808\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Shp-2 is critical for ERK activation and metabolic engagement (glycolysis and respiration) downstream of IL-15 receptor in NK cells. Shp-2-deficient NK cells show dramatic defect in ERK activation and reduced metabolic burst upon IL-15/IL-2 stimulation, leading to impaired proliferation and survival. ERK and mTOR cascade inhibition phenocopied Shp-2 deficiency.\",\n      \"method\": \"NK cell-specific conditional Shp-2 KO, ERK phosphorylation assay, Seahorse metabolic flux analysis, pharmacological ERK/mTOR inhibitor epistasis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic KO plus pharmacological epistasis plus metabolic assay, multiple orthogonal methods\",\n      \"pmids\": [\"30926899\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Genetic deletion of Ptpn11 profoundly inhibits tumor development in mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) and non-small-cell lung cancer mouse models. SHP-2 is necessary for resistance mechanisms upon MEK blockade. Dual SHP2/MEK inhibition achieves synergistic tumor growth control in KRAS-mutant PDAC and NSCLC.\",\n      \"method\": \"Genetic Ptpn11 deletion in KRAS-driven mouse tumor models, MEK inhibitor combination, patient-derived organoids and xenograft models\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo genetic KO plus pharmacological combination, multiple tumor models including human patient-derived material\",\n      \"pmids\": [\"29808009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"X-ray crystallography identified a second allosteric binding site on SHP2 at the interface of the N-terminal SH2 and PTP domains (distinct from the tunnel-like SHP099 site). SHP244 binds and stabilizes the inactive closed conformation of SHP2 at this site. Simultaneous occupation of both allosteric sites is possible, demonstrating cooperative dual allosteric inhibition and enhanced MAPK pathway suppression.\",\n      \"method\": \"X-ray crystallography of SHP2/inhibitor complexes, cooperative biochemical inhibition assays, DUSP6 mRNA assay in cancer cells, structure-based design\",\n      \"journal\": \"ACS chemical biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures of multiple complexes plus biochemical cooperativity assay\",\n      \"pmids\": [\"29304282\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SHP-2 directly interacts with ICAM-1 and VE-cadherin in endothelial cells. SHP-2 downregulation enhanced neutrophil adhesion but inhibited transmigration. ICAM-1 activation leads to SHP-2-mediated Src activation and VE-cadherin switching from ICAM-1 association to actin association; SHP-2 downregulation prevented ICAM-1-VE-cadherin association and promoted VE-cadherin-actin association.\",\n      \"method\": \"siRNA knockdown of SHP-2, co-immunoprecipitation of ICAM-1/SHP-2/VE-cadherin, neutrophil adhesion/transmigration assay, in vivo LPS lung model\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus siRNA KD plus in vivo model, single lab\",\n      \"pmids\": [\"28701303\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In sepsis, ROS-dependent inactivation of SHP-2 in endothelial cells drives vascular dysfunction. SHP-2 directly interacts with the IL-1R1 adaptor MyD88 via its tyrosine 257, resulting in reduced binding of p85/PI3K to MyD88. SHP-2 activity inversely correlates with adhesion molecule expression through p38 MAPK and NF-κB.\",\n      \"method\": \"Proximity ligation assay for SHP-2/MyD88 interaction, SHP-2 phosphatase activity assay, ROS inhibitor rescue, in vivo sepsis model, in vitro endothelial cell model, Y257 mutagenesis\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proximity ligation assay plus phosphatase assay plus site-directed mutagenesis, single lab\",\n      \"pmids\": [\"30905847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Intestinal epithelial cell-specific deletion of SHP-2 leads to severe colitis with hyperactivation of Stat3 and NF-κB, decreased claudin expression and enhanced intestinal permeability. Antibiotic treatment markedly impaired colitis development, indicating a microbiota-dependent mechanism.\",\n      \"method\": \"Intestinal epithelial cell-specific conditional KO (SHP-2(IEC-KO) mice), histology, cytokine analysis, intestinal permeability assay, Western blot for Stat3/NF-κB, antibiotic treatment\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tissue-specific genetic KO with comprehensive mechanistic analysis, multiple orthogonal methods\",\n      \"pmids\": [\"23530062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In myeloid cells, SHP-2 restrains GM-CSF-induced phosphorylation of transcription factors HOXA10 and IRF8, which regulate myeloid differentiation and monocytic-moDC lineage commitment. GM-CSF induces phosphorylation of PD-1 and recruitment of PD-1-SHP-2 to the GM-CSF receptor. Myeloid-specific deletion of SHP-2 or PD-1 diminishes tumor growth via enhanced myeloid differentiation.\",\n      \"method\": \"Myeloid-specific conditional SHP-2 or PD-1 KO mice, RNA-seq/GSEA, HOXA10/IRF8 phosphorylation assay, co-immunoprecipitation of PD-1-SHP-2 with GM-CSF receptor, tumor growth assay\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific genetic KO, co-IP of receptor complex, downstream TF phosphorylation analysis, multiple orthogonal methods\",\n      \"pmids\": [\"36581713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"BIT (brain immunoglobulin-like molecule with tyrosine-based activation motifs) associates with SHP-2 via its tyrosine-phosphorylated TAMs upon neurotrophin (NGF, BDNF, NT-3) stimulation, and this association potently stimulates SHP-2 phosphatase activity in neurons.\",\n      \"method\": \"Co-immunoprecipitation after neurotrophin treatment, in vitro SHP-2 phosphatase activation assay with pY-BIT\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus phosphatase activation assay, single lab\",\n      \"pmids\": [\"10098842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RSK (p90 ribosomal S6 kinase) phosphorylates Gab2 on conserved residues upon Ras/MAPK pathway activation, and this phosphorylation inhibits recruitment of SHP-2 to Gab2 in response to growth factors. An unphosphorylatable Gab2 mutant promotes invasion-like phenotype and increased cell motility, indicating that RSK-mediated Gab2 phosphorylation constitutes a negative-feedback loop restricting Gab2-dependent SHP-2 recruitment and epithelial cell motility.\",\n      \"method\": \"In vitro RSK kinase assay with Gab2, phosphosite mutagenesis, co-immunoprecipitation of Gab2-SHP-2 after growth factor stimulation, invasion/motility assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay plus co-IP plus mutagenesis plus functional cell assay, single lab\",\n      \"pmids\": [\"23401857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Crystal structures of wild-type SHP2 and five NS/LS-associated PTPN11 mutants reveal local conformational changes caused by each mutation. NS mutations shift conformational equilibrium toward the active open state; LS mutations have distinct structural consequences consistent with loss of catalytic activity. Structural analysis provides mechanistic insight into the distinct catalytic properties of disease-associated mutants.\",\n      \"method\": \"X-ray crystallography of WT and mutant SHP2 proteins\",\n      \"journal\": \"BMC structural biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structures of multiple disease mutants with direct conformational comparison, single study\",\n      \"pmids\": [\"24628801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Gab1-SHP-2 interaction is required for EGF-induced Ras activation and epidermal proliferation. Gab1(Y627F) deficient in SHP-2 binding or dominant-negative SHP-2(C459S) reduced active Ras and downstream MAPK levels and initiated keratinocyte differentiation. Active Ras rescued the differentiation induced by Gab1(Y627F) and SHP-2(C459S), placing Gab1 and SHP-2 upstream of Ras in epidermal homeostasis.\",\n      \"method\": \"Gab1(Y627F) and SHP-2(C459S) overexpression in epidermal cells, Ras activity assay, Ras rescue epistasis, tissue reconstruction model, Gab1-/- murine epidermis analysis\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic tools (dominant negative, site mutant, KO epidermis) plus Ras activity assay plus genetic rescue\",\n      \"pmids\": [\"12370245\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"SHP-2 is required for Ras-dependent JNK activation by insulin and EGF. A catalytically inactive SHP-2(C/S) mutant markedly inhibited Ras activation in response to insulin without affecting insulin-induced tyrosine phosphorylation of substrates. SHP-2(C/S) did not inhibit JNK activation induced by constitutively active Ras(V12), placing SHP-2 at the level of or upstream of SOS in insulin-mediated JNK activation.\",\n      \"method\": \"Catalytically inactive SHP-2(C/S) overexpression, JNK/ERK activation assay, Ras-GTP loading assay, dominant-negative Ras/Rac epistasis, PI3K inhibitor\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple epistatic experiments with defined pathway placement, single lab\",\n      \"pmids\": [\"10671568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"SHP-2 catalytic activity suppresses caspase 3-mediated apoptosis by regulating IGF-1-dependent PI3K and Akt activation. Catalytically inactive SHP-2 inhibited IGF-1-induced PI3K and Akt activation; SHP-2(Ex3-/-) fibroblasts showed enhanced caspase 3 activation upon etoposide treatment, rescued by re-introduction of wild-type SHP-2 or a caspase 3 inhibitor.\",\n      \"method\": \"Catalytically inactive SHP-2 overexpression, SHP-2(Ex3-/-) fibroblasts, PI3K/Akt assay, caspase 3 activity assay, WT-SHP-2 rescue, RNAi knockdown\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic deletion plus catalytic mutant plus rescue plus downstream kinase assay, single lab\",\n      \"pmids\": [\"15040005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SHP-2 and Src are exclusively localized in brain (not muscle, heart, liver, or kidney) mitochondria. In brain mitochondria, ATP induces Src autophosphorylation at Tyr-416 (activation), and SHP-2 is present at this location; Src inhibition partially reversed ATP-induced increases in oxidative phosphorylation complexes I, III, and IV activity.\",\n      \"method\": \"Subcellular fractionation and immunodetection of PTP-1B, SHP-2, and Src in isolated mitochondria from multiple rat tissues, oxidative phosphorylation complex activity assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — fractionation/localization with functional inference, but SHP-2's own activity at this location was not directly tested; single lab\",\n      \"pmids\": [\"18583343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In C2C12 myoblasts, FGF-2 stimulation induces SHP-2 complex formation with tyrosyl-phosphorylated FRS-2α. Both catalytic activity and (to a lesser extent) the Grb2-binding/tyrosyl-phosphorylation sites of SHP-2 are required for maximal FGF-2-induced Erk activation. A constitutively active SHP-2 mutant represses myogenesis via an Erk-independent pathway and induces hyper-tyrosyl phosphorylation of FRS-2α.\",\n      \"method\": \"Co-immunoprecipitation of SHP-2 with FRS-2α, Erk/Elk-1 activation assay, constitutively active and catalytically inactive SHP-2 overexpression, myogenesis assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus catalytic/constitutive mutants plus functional myogenesis assay, single lab\",\n      \"pmids\": [\"11997521\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SHP-2 (PTPN11) is a cytoplasmic protein tyrosine phosphatase with two SH2 domains that is held in an autoinhibited closed conformation by intramolecular N-SH2/PTP domain interaction; binding of phosphotyrosine-containing ligands (growth factor receptors, docking proteins such as GAB1/FRS-2, and inhibitory receptor ITSMs such as PD-1) via its SH2 domains relieves autoinhibition and activates catalysis. It acts as a positive regulator of RAS/MAPK and PI3K/AKT signaling downstream of multiple receptor tyrosine kinases, cytokine receptors, and integrins—in part by dephosphorylating negative regulators (e.g., p190-B RhoGAP, PDGFR, STAT5A) and stabilizing signaling complexes—while also serving as a negative regulator of JAK/STAT, RhoA (via RhoGAP dephosphorylation), and TRIF-dependent TLR/TBK1 pathways; disease-causing gain-of-function mutations (Noonan syndrome, leukemia) shift the conformational equilibrium toward the active state, whereas loss-of-function mutations (LEOPARD syndrome) abolish catalytic activity, and both classes disrupt convergence/extension cell movements, cardiac development, and hematopoiesis through dysregulation of ERK, mTOR, RhoA/ROCK, and Ca²⁺/NFAT signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SHP-2 (PTPN11) is a cytoplasmic protein tyrosine phosphatase that serves as a central positive amplifier of receptor tyrosine kinase and cytokine signaling toward the RAS/MAPK and PI3K/AKT pathways, while acting as a negative regulator of several inhibitory and inflammatory circuits [#8, #12, #34]. Its activity is governed by a conformational switch: disease-associated Noonan-syndrome mutations cluster at the interacting N-SH2/PTP interface and shift the equilibrium toward the active open state, whereas LEOPARD-syndrome mutations abolish catalytic activity, mechanisms confirmed by crystallography of wild-type and mutant proteins [#0, #47]. Physiologically, the SH2 domains engage phosphotyrosine ligands\\u2014growth-factor receptors, docking proteins such as GAB1 and FRS-2, and inhibitory receptor ITSMs such as PD-1\\u2014to relieve autoinhibition and stimulate catalysis; PD-1 engagement bridges two receptor tails through both SH2 domains to robustly activate the enzyme [#6, #28, #32, #48]. SHP-2 promotes RAS activation upstream of SOS and drives sustained ERK signaling downstream of EGF, PDGF, FGF, and insulin, paradoxically enhancing MAPK output even while dephosphorylating receptors such as PDGFR [#16, #48, #49, #34], and it supports PI3K/AKT/mTOR signaling required for survival, cell size control, and tumorigenesis [#12, #22, #30]. Direct substrates include p190-B RhoGAP (linking SHP-2 to RhoA activation and myogenesis), STAT5A, IRS-1, and PDGFR, and unbiased phosphoproteomics establishes SHP-2 as a master regulator of the PDGFR phosphotyrosine network controlling targets including RASA1, cortactin, and GAB1 [#9, #13, #15, #34]. As a negative regulator it dampens JAK/STAT signaling, restrains TRIF-dependent TLR/TBK1 responses via a phosphatase-independent C-terminal interaction with TBK1, and limits Schwann cell, T-cell, NK-cell, osteoclast, and myeloid responses [#4, #21, #18, #20, #38, #36, #44]. SHP-2 is essential for hematopoietic and lymphoid development, cell spreading and migration through FAK/Src, and convergence-extension movements during gastrulation via Src-family kinases and RhoA [#3, #33, #29]. Its activity is itself tuned by oxidative and nitrosative modification of the active-site cysteine and by Abl-mediated phosphorylation feedback [#23, #20, #25]. PTPN11 mutations cause Noonan syndrome and LEOPARD-syndrome/hypertrophic cardiomyopathy and underlie somatic transformation in juvenile myelomonocytic leukemia and KRAS-driven solid tumors [#0, #30, #5, #39].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that SHP-2 is physically coupled to activated growth factor receptors, providing the first link between the phosphatase and RTK signaling.\",\n      \"evidence\": \"Co-IP and SH2 direct-binding assays showing SH-PTP2 binds activated EGFR/PDGFR via its N-SH2 domain and is itself tyrosine-phosphorylated\",\n      \"pmids\": [\"8514779\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not determine functional consequence of receptor binding\", \"Substrates downstream of receptor recruitment not identified\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Showed SHP-2 actively dephosphorylates a defined substrate (IRS-1) and that its SH2 domains allosterically enhance catalysis, foreshadowing the autoinhibition model.\",\n      \"evidence\": \"In vitro phosphatase assay comparing full-length versus SH2-deleted enzyme on pY-IRS-1\",\n      \"pmids\": [\"7515062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SH2-mediated activation not resolved\", \"Physiological relevance of IRS-1 dephosphorylation not tested in vivo\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Resolved that SHP-2 has opposing roles on different pathways\\u2014positively engaging ERK while negatively regulating JAK/STAT.\",\n      \"evidence\": \"gp130 Y118F receptor mutant in ES cells, MEK inhibitor, and Shp-2-deficient fibroblasts with elevated STAT1 phosphorylation rescued by WT re-expression\",\n      \"pmids\": [\"10364425\", \"10022928\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT substrate dephosphorylation not biochemically demonstrated here\", \"Mechanism of ERK activation versus receptor dephosphorylation paradox unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Defined the domain requirements for SHP-2 function and placed it in cell adhesion/cytoskeletal control via FAK and Src.\",\n      \"evidence\": \"Xenopus mesoderm induction with domain-deletion/chimera mutants; Shp-2 mutant fibroblasts with impaired spreading and reduced FAK dephosphorylation\",\n      \"pmids\": [\"9418864\", \"9694867\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct FAK substrate relationship not established by substrate trapping\", \"PTP-domain specificity determinants only partially mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Placed SHP-2 epistatically upstream of RAS and RhoA, defining its dual control of MAPK and small-GTPase signaling.\",\n      \"evidence\": \"Catalytically inactive SHP-2 blocking insulin/EGF Ras activation upstream of SOS; genetic and calpeptin perturbation elevating active RhoA\",\n      \"pmids\": [\"10671568\", \"11114521\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct RhoA-pathway substrate not yet identified in these studies\", \"Mechanism linking phosphatase activity to RAS-GTP loading unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified PTPN11 gain-of-function mutations as the cause of Noonan syndrome, linking conformational activation to human disease.\",\n      \"evidence\": \"Mutation screening plus energetics-based structural analysis of N-SH2 mutants showing equilibrium shift to active state\",\n      \"pmids\": [\"11704759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct measurement of mutant phosphatase activity not in this study\", \"Downstream effector dysregulation not yet defined\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated SHP-2 as a target hijacked by a bacterial effector and required for PI3K/AKT and hematopoietic development.\",\n      \"evidence\": \"CagA complex formation activating SHP-2; SH2-domain-dependent PI3K p85 co-IP and Akt activation; RAG-2 blastocyst complementation showing no lymphoid development in Shp-2-null cells\",\n      \"pmids\": [\"11743164\", \"11593409\", \"11159516\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise mechanism by which SHP-2 promotes PI3K recruitment not fully defined\", \"Relevant hematopoietic substrates not identified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Established GAB1/FRS-2 docking-protein recruitment as the route by which SHP-2 drives RAS activation and controls cell fate.\",\n      \"evidence\": \"Gab1(Y627F) and SHP-2(C459S) reducing active Ras with Ras rescue; FGF-induced SHP-2/FRS-2\\u03b1 complex required for ERK activation in myoblasts\",\n      \"pmids\": [\"12370245\", \"11997521\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrate dephosphorylated to enable Ras activation not pinpointed\", \"Erk-independent repression of myogenesis mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified STAT5A as a direct SHP-2 substrate and tied somatic PTPN11 mutations to leukemia through RAS.\",\n      \"evidence\": \"pY-Stat5A affinity purification and dephosphorylation kinetics in Shp-2-deficient cells; JMML mutation screening mutually exclusive with RAS/NF1 plus Ba/F3 growth-factor-independence\",\n      \"pmids\": [\"12615921\", \"14644997\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"JMML study showed negative ERK/Akt hyperactivation, leaving effector mechanism open\", \"Leukemogenic substrate spectrum not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Connected SHP-2 conformational activation in disease mutants to sustained GAB1 binding and ERK output, and identified p190-B RhoGAP as a direct substrate linking SHP-2 to RhoA-dependent myogenesis.\",\n      \"evidence\": \"Noonan mutant phosphatase assays with GAB1-FF dominant negative; substrate-trapping mutants identifying p190-B RhoGAP with RhoA activity readout\",\n      \"pmids\": [\"14974085\", \"15169898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How dephosphorylation of a RhoGAP activates rather than inhibits RhoA mechanistically incomplete\", \"Generalizability of GAB1-sustained ERK to all mutants untested\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Revealed redox control of SHP-2 and context-dependent negative regulation of neurotrophin and TCR signaling.\",\n      \"evidence\": \"TCR-induced ROS oxidation of active-site cysteine with LAT/Gads/SLP-76 recruitment; Ca2+-enhanced SHP-2/TrkB association inhibiting BDNF signaling reversed by Shp2 deletion\",\n      \"pmids\": [\"15933714\", \"15650750\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab redox findings without independent confirmation\", \"Direct TrkB dephosphorylation versus indirect inhibition not distinguished\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Defined phosphatase-independent functions of SHP-2 as a scaffold/chaperone, restraining innate immune TLR/TBK1 signaling and stabilizing Bcr-Abl.\",\n      \"evidence\": \"C-terminal domain binding to TBK1 with SHP-2-deficient cytokine analysis; Hsp90 co-IP and proteasome-dependent p210 Bcr-Abl degradation upon SHP-2 loss\",\n      \"pmids\": [\"17157040\", \"17003374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of non-catalytic TBK1/Hsp90 interactions not defined\", \"Balance between catalytic and scaffold roles in leukemia not quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Placed SHP-2 in cardiac progenitor maintenance and gastrulation movements through FGF/FRS-2, Src-family kinases, and RhoA.\",\n      \"evidence\": \"Xenopus cardiac progenitor assays with FRS-2 co-IP and FGF rescue; zebrafish morpholino knockdown rescued by active Fyn/Yes/RhoA, with patient mutants causing convergence-extension defects\",\n      \"pmids\": [\"17928416\", \"18159945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrates mediating C&E movements not identified\", \"How both GOF and LOF mutants converge on the same defect mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established tissue-specific roles of SHP-2 spanning tumor suppression, Schwann cell ErbB signaling, and mTOR-driven cardiomyopathy.\",\n      \"evidence\": \"Hepatocyte Shp2/Stat3 double KO abolishing HCC; conditional Schwann-cell KO with Src-inhibitor phenocopy; PDGFR\\u03b1 glioma model with PI3K rescue; cardiomyocyte Q510E transgenic rescued by rapamycin\",\n      \"pmids\": [\"21575863\", \"19805360\", \"21393858\", \"22058153\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Context-dependent tumor suppressor versus oncogenic roles not mechanistically unified\", \"Direct substrates in each tissue largely undefined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Extended SHP-2 function to actin/ROCK control of cardiac development, osteoclast fusion, and nutrient-sensing mTOR signaling.\",\n      \"evidence\": \"Xenopus Noonan mutant cardiac defects rescued by ROCK inhibition; osteoclast-specific KO osteopetrosis with RANKL/Nfatc1 defect; myoblast leucine-induced S6K1 activation via PLC\\u03b24/Ca2+\",\n      \"pmids\": [\"22278918\", \"25593124\", \"23129808\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct substrate connecting SHP-2 to ROCK and Ca2+ pathways not identified\", \"Leucine-sensing mechanism is single-lab\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Broadened SHP-2 into vascular, endothelial, and intestinal barrier regulation and revealed negative-feedback loops controlling its recruitment.\",\n      \"evidence\": \"S-nitrosylation inhibiting neuronal SHP-2/ERK; ICAM-1/VE-cadherin interactions in endothelium; IEC-specific KO causing microbiota-dependent colitis; RSK phosphorylation of Gab2 limiting SHP-2 recruitment\",\n      \"pmids\": [\"23382182\", \"28701303\", \"23530062\", \"23401857\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Several endothelial/feedback findings are single-lab\", \"Direct substrates in barrier regulation not mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Provided direct structural evidence distinguishing Noonan (activating) from LEOPARD (inactivating) mutations.\",\n      \"evidence\": \"X-ray crystallography of wild-type and five disease-mutant SHP2 proteins\",\n      \"pmids\": [\"24628801\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of the autoinhibitory switch not captured by static structures\", \"Allosteric ligand-binding states not resolved here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Uncovered a cell-cycle role for SHP-2 at mitotic structures, linking GOF mutations to chromosomal instability via Plk1/c-Src.\",\n      \"evidence\": \"Immunofluorescence localization to kinetochore/centrosome/midbody and Plk1/c-Src kinase assays in Ptpn11 GOF knock-in MEFs\",\n      \"pmids\": [\"26755576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mitotic substrate of SHP-2 not identified\", \"Single-study mitotic localization needs independent confirmation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined SHP-2 as a master regulator of the PDGFR phosphoproteome and a druggable node for KRAS-driven cancer, with a second allosteric site for inhibition.\",\n      \"evidence\": \"Quantitative phosphoproteomics with allosteric inhibitor SHP099; genetic Ptpn11 deletion in KRAS PDAC/NSCLC models with MEK-inhibitor synergy; crystallography of a second allosteric SHP244 site\",\n      \"pmids\": [\"29514104\", \"29808009\", \"29304282\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct versus indirect substrates within the phosphoproteome not fully separated\", \"Resistance mechanisms to dual SHP2/MEK inhibition incompletely defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Tied SHP-2 to immune-cell metabolism and inflammatory vascular dysfunction.\",\n      \"evidence\": \"NK-cell-specific KO with ERK and Seahorse metabolic defects; sepsis model showing ROS-inactivated SHP-2 interacting with MyD88 via Y257\",\n      \"pmids\": [\"30926899\", \"30905847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"MyD88 interaction is single-lab via proximity ligation\", \"Metabolic regulation mechanism downstream of ERK not detailed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Provided the biophysical basis for SHP-2 activation by inhibitory immune receptors through dual-ITSM bridging of PD-1.\",\n      \"evidence\": \"ITC, live-cell PD-1 dimerization, and enzymatic activation assays showing both SH2 domains engage two pY-ITSM-Y248 tails\",\n      \"pmids\": [\"32184441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream substrates dephosphorylated upon PD-1 engagement not defined here\", \"Stoichiometry in physiological synapses not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Connected the PD-1/SHP-2 module to myeloid differentiation and tumor immunity beyond T cells.\",\n      \"evidence\": \"Myeloid-specific SHP-2 or PD-1 KO with PD-1\\u2013SHP-2 recruitment to GM-CSF receptor and HOXA10/IRF8 phosphorylation analysis\",\n      \"pmids\": [\"36581713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HOXA10/IRF8 are direct SHP-2 substrates not established\", \"Catalytic versus scaffold contribution to myeloid effect not separated\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SHP-2's small set of validated direct substrates accounts for its simultaneous positive (RAS/MAPK, PI3K) and negative (JAK/STAT, RhoA, TLR) outputs across tissues remains the central unresolved question.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Few direct catalytic substrates identified relative to breadth of phenotypes\", \"Tissue-specific substrate selection mechanism unknown\", \"Integration of catalytic and scaffold/chaperone functions not unified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [9, 13, 15, 16, 34, 35]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [9, 13, 15, 35]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [6, 12, 21, 28]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [8, 28]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [20, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [8, 12, 34]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [3, 31]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [51]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 12, 34, 48, 49]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 5, 30, 39, 47]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [4, 20, 21, 38, 44]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [14, 18, 29, 31, 32]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [50]}\n    ],\n    \"complexes\": [\"LAT-Gads-SLP-76 complex\", \"PD-1:PD-1 dimer\"],\n    \"partners\": [\"GAB1\", \"FRS-2\", \"PD-1\", \"JAK2\", \"TBK1\", \"GRB2\", \"STAT5A\", \"PDGFR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}